University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2015

Therapeutic Applications and Specificity of Action of Designer
Nucleases for Precision Genome Engineering
Chukwuka Anthony Didigu
University of Pennsylvania, chuka.didigu@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biology Commons, Biomedical Commons, and the Microbiology Commons

Recommended Citation
Didigu, Chukwuka Anthony, "Therapeutic Applications and Specificity of Action of Designer Nucleases for
Precision Genome Engineering" (2015). Publicly Accessible Penn Dissertations. 1042.
https://repository.upenn.edu/edissertations/1042

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1042
For more information, please contact repository@pobox.upenn.edu.

Therapeutic Applications and Specificity of Action of Designer Nucleases for
Precision Genome Engineering
Abstract
Designer nucleases allow for the precise modification of a given DNA sequence by the introduction of a
sequence-specific double strand break. This targeted genetic engineering confers the ability to modify
genomes of complex organisms, and has far-reaching applications in human medicine, agriculture, and
biotechnology. As these nucleases act in a sequence specific manner, understanding their specificity is of
paramount importance to prevent potentially genotoxic side effects. In this thesis, I assessed the ability
of a class of designer nucleases (ZFNs)--zinc finger nucleases--to simultaneously inactivate two genes
encoding entry factors required for HIV infection in human CD4 T cells. Additionally, I sought to develop a
high-throughput means of identifying sites of designer nuclease off-target activity across the genome, in
an effort to better understand the factors governing designer nuclease specificity. This work
demonstrates the ability of ZFNs to simultaneously modify two distinct genetic loci in primary human
CD4 T cells--the main target of HIV infection. These gene-modified cells are protected from HIV infection
and represent a novel means of treating--and potentially curing HIV infection. This work also
demonstrates that DNA double-strand breaks introduced by a single designer nuclease at on- and offtarget loci can result in the formation of genomic rearrangements. Taken together, this work advances in
the field of genome engineering on two fronts--a novel therapeutic application of designer nucleases and
a novel means of detecting off-target genomic modification.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Robert W. Doms

Second Advisor
John E. Wherry

Keywords
CRISPR, Designer nuclease, Genome editing, HIV, TALEN, Zinc Finger nuclease

Subject Categories
Biology | Biomedical | Microbiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1042

THERAPEUTIC APPLICATIONS AND SPECIFICITY OF ACTION OF
DESIGNER NUCLEASES FOR PRECISION GENOME ENGINEERING
Chukwuka Anthony Didigu
A DISSERTATION
In Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
In Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2015

Supervisor of Dissertation
_________________________________
Robert W. Doms, Professor of Pathology and Laboratory Medicine

Graduate Group Chairperson
____________________________________
Dan Kessler, Associate Professor of Cell and Developmental Biology

Dissertation Committee
John E. Wherry (Chair), Associate professor of Microbiology
Beatrice Hahn, Professor of Medicine and Microbiology
Carl H. June, Professor of Pathology and Laboratory Medicine
David B. Roth, Professor of Pathology and Laboratory Medicine
	
  
	
  

THERAPEUTIC APPLICATIONS AND SPECIFICITY OF ACTION OF
DESIGNER NUCLEASES FOR PRECISION GENOME ENGINEERING
COPYRIGHT
2015
Chukwuka Anthony Didigu

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 3.0
License

To view a copy of this license, visit
http://creativecommons.org/licenses/by-ny-sa/2.0/

	
  
	
  

DEDICATION
There are a number of people I have to thank, for their tireless support over the
last few years. I would like to thank my family, for their understanding. I would
like to thank the University of Pennsylvania MSTP—particularly Maggie Krall—for
always knowing the right thing to do. And I would like to thank my friends—
especially Dr Gregory Charak—for never letting me forget what really matters.
Finally I would like to thank my mentor, Dr Robert W Doms. His mentoring style,
keen intellect, logical thought process, and warmth are traits that drew me to his
lab and that made the last three years the single most instructive experience I
have ever had. To him, I am truly grateful.

iii	
  
	
  

ACKNOWLEDGMENT
This work would not have been possible without the efforts of a number of people
both within and outside of the University of Pennsylvania. As such I would like to
thank the following people for their immeasurable contributions to this thesis—Dr
Craig Wilen, Dr Carl June, Dr Frederick bushman, Dr James Riley, Dr Andrew
Stern, Nirav Malani, Mary Jane Drake, Dr Paul Bates, Dr Nicholas Parrish, Dr
Beatrice Hahn, Dr Jason Wojcechowskyj, Zahra Parker, and Val hardy.

	
  

iv	
  
	
  
	
  

ABSTRACT
THERAPEUTIC APPLICATIONS AND SPECIFICITY OF ACTION OF
DESIGNER NUCLEASES FOR PRECISION GENOME ENGINEERING
Chukwuka A. Didigu
Robert W. Doms
Designer nucleases allow for the precise modification of a given DNA sequence
by the introduction of a sequence-specific double strand break. This targeted
genetic engineering confers the ability to modify genomes of complex organisms,
and has far-reaching applications in human medicine, agriculture, and
biotechnology. As these nucleases act in a sequence specific manner,
understanding their specificity is of paramount importance to prevent potentially
genotoxic side effects. In this thesis, I assessed the ability of a class of designer
nucleases (ZFNs)—zinc finger nucleases—to simultaneously inactivate two
genes encoding entry factors required for HIV infection in human CD4 T cells.
Additionally, I sought to develop a high-throughput means of identifying sites of
designer nuclease off-target activity across the genome, in an effort to better
understand the factors governing designer nuclease specificity. This work
demonstrates the ability of ZFNs to simultaneously modify two distinct genetic
loci in primary human CD4 T cells—the main target of HIV infection. These genemodified cells are protected from HIV infection and represent a novel means of
treating—and potentially curing HIV infection. This work also demonstrates that
DNA double-strand breaks introduced by a single designer nuclease at on- and
off-target loci can result in the formation of genomic rearrangements. Taken
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together, this work advances in the field of genome engineering on two fronts—a
novel therapeutic application of designer nucleases and a novel means of
detecting off-target genomic modification.
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Chapter 1. Designer nucleases are a flexible tool for precision genome
engineering
I. Genome engineering using designer nucleases
The ability to introduce stable, heritable, genetic modifications in complex
organisms provides a unique opportunity to alter such organisms for therapeutic,
biotechnology and research purposes. This process of genome engineering can
be achieved using a diverse family of molecules called designer nucleases.
Designer nucleases are chimeric molecules that can be engineered to bind a
given DNA sequence and once bound to their target, introduce a double-strand
break (DSB). This DSB serves as the nexus for a number of genomic alterations
including inactivation of target genes, gene correction, and the insertion of new
coding sequences (reviewed in (1)). Inactivation of a target gene requires DSB
repair to occur via the error-prone cellular non-homologous end-joining (NHEJ)
pathway, which most often generates random insertions and deletions that result
in a non-functional gene product (2). Conversely, the presence of a DNA
template with homology to the region surrounding the DSB—such as a sister
chromatid—allows for DSB repair to occur via the higher fidelity homologous
repair pathway. As such, the concomitant introduction of a DSB by a designer
nuclease and delivery of a custom DNA template with homology to the site of the
DSB allows for the introduction of an investigator-designed DNA sequence into a
given locus. These sequences can range from single base pair substitutions to
the insertion of large segments of coding DNA. To date, the three most widely
1	
  

used designer nucleases include Zinc Finger Nucleases (ZFNs), Transcription
Activator-Like Effector Nucleases (TALENs) and Clustered Regularly
Interspaced Short Palindromic Repeat-associated nucleases (the CRISPR/Cas
system).
II. Zinc Finger Nucleases
ZFNs consist of a DNA-binding Cys2-His2 zinc finger protein (ZFP) fused
to the nuclease domain of the dimeric FokI restriction endonuclease (3-5). The
Cys2-His2 zinc finger domain is one of the most common DNA binding motifs
found in eukaryotic transcription factors. These domains have a ββα-fold
conformation, and amino acids in the α-helix of the zinc finger contact 3-4 base
pairs in the major groove of DNA. The ability to target longer sequences was
made possible by the development a polypeptide linker that allows for the
generation of tandem arrays of zinc fingers, and has resulted in enhanced ZFN
specificity (6). To date, ZFPs that bind most of the 64 possible DNA triplets have
been designed, greatly aiding the synthesis of ZFNs that target sequences long
enough to ensure genome-wide specificity.
ZFNs function as a pair, and to introduce a double stranded break at a
given locus, members of a ZFN pair must first bind their target DNA sequence,
with each half of the pair binding to an opposite strand of DNA. This binding
event brings the members of a ZFN pair into close enough proximity to allow for
the formation of a catalytically active nuclease complex following dimerization of
the nuclease domains, which then cleaves the underlying DNA sequence. ZFN
2	
  	
  
	
  

binding is highly specific, as cleavage will only occur if the ZFNs recognize and
bind to an appropriate sequence, and the members of the ZFN pair bind in the
correct orientation with a spacer requirement of 5-6 base pairs of DNA between
each ZFP target sequence. Additionally, the FokI nuclease domain which
normally functions as a homodimer, has recently been modified to function as a
heterodimer by introducing charged residues at the nuclease dimer interface and
placing these positively and negatively charged residues onto opposite sides of
the monomers that comprise the FokI dimer(7). As two positively or negatively
charged FokI monomers will not interact, these alterations allow the FokI
nuclease to function as an obligate heterodimer, eliminating the possibility of
one-half of a ZFN pair binding on opposite DNA strands at an off-target site and
introducing an unwanted DSB(7).
Despite their ability to target a wide array of sequences, ZFNs can be
quite challenging to design owing in large part to the context-dependent nature of
their DNA binding domains i.e. DNA triplet binding preference of each zinc finger
domain in a ZFP array is influenced by any ZFPs to which it is directly linked. As
such, early ZFP arrays used to design ZFNs displayed a high failure rate with
many ZFNs failing to bind and cleave their target sequences. Recent
improvements in the ZFN assembly platforms have made ZFN design somewhat
easier, but these issues of context dependence and the relatively high cost of
making ZFNs has led many groups to explore alternative platforms to accomplish
precision genome editing.
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III. Transcription Activator-Like Effector Nucleases
TALENs bear a similar overall architecture to ZFNs in that they also
function as a pair, with a DNA-binding protein domain fused to the nuclease
domain of the FokI endonuclease. The TALEN DNA binding domain is based on
the transcription activator-like (TAL) DNA-binding proteins found in Xanthomonas
bacteria. Unlike ZFPs, the DNA binding of TAL effectors is almost entirely free of
context dependent effects. Each TAL repeat usually consists of 33-35 amino
acids, where all the residues are highly conserved except for residues in the 12
and 13 position. Together these two amino acids are termed the repeat-variable
diresidue (RVD) and they confer the nucleotide specificity of TAL effectors.
Specifically, the 13th residue contacts a single nucleotide in the major groove of
DNA while the 12th residue stabilizes the short loop structure formed by the RVD
(8,9). As each RVD usually binds a single nucleotide, modular assembly of TAL
repeats can be used to generate TAL protein arrays capable of binding any DNA
sequence as long as that sequence begins with a Thymine base. While TALENs
can also be used with obligate heterodimeric FokI nuclease domains, and can
target long sequences to achieve genome-wide specificity as is done with ZFNs,
they have a more variable spacer requirement than ZFNs, usually in the range of
10-20bp and this could, in theory, contribute to an increased rate of off-target
binding activity. Additionally, the repetitive nature of the TAL arrays makes them
difficult to synthesize, and so while TALENs lack the context-dependent effects
seen with ZFNs, their variable spacer lengths and challenging synthesis have
hindered their widespread adoption.
4	
  	
  
	
  

IV. The CRISPR/Cas system
The CRISPR/Cas system is the only known form of adaptive immunity
against phage infection in prokaryotes, and is made up of two main
components—arrays of clustered regularly interspaced short palindromic
repeats (CRISPRs), and CRISPR associated (Cas) genes that are usually
located adjacent to the CRISPR arrays. Following phage infection, the
CRISPR/Cas system functions by incorporating phage DNA into the host
genome, synthesizing CRISPR RNAs (crRNA) with complementarity to the
incorporated/invading phage DNA, forming crRNA-phage DNA hybrids, and
degrading these hybrids through the nuclease activity of the Cas proteins
(reviewed in (10)). Despite the diversity of bacteria and archaea with naturally
occurring CRISPR/Cas systems, these systems all have the same overall
architecture. CRISPR loci contain arrays of short nucleotide repeats separated
by non-repeating spacer sequences. These spacer sequences, which are
derived from invading phage, are called protospacers, and are flanked by short
DNA sequences called protospacer adjacent motifs (PAMs). There exist three
main CRISPR/Cas systems—Type I, II and III, and of these the type II
CRISPR/Cas system is arguably the most well studied. In this system,
transcription at a CRISPR locus generates a pre-crRNA, which is then processed
by Cas proteins into a crRNA containing, among other things, the phage derived
protospacer sequence. This crRNA then binds a trans-activating crRNA
(tracrRNA) and this complex guides sequence specific binding of the crRNA to
the invading phage DNA and subsequent cleavage of the resulting RNA-DNA
5	
  	
  
	
  

hybrid by the Cas9 nuclease. Several recent studies have recreated the
CRISPR/Cas system by generating a hybrid RNA—generally termed a guide
RNA or gRNA(11-13). This gRNA has both complementarity to a target sequence
located adjacent to a PAM sequence (similar to the crRNA), and a stem loop
structure (similar to that present in the tracrRNA) that recruits the Cas nuclease
(Cas9) to the site of the RNA-DNA complex. As such, co-delivery of a gRNA and
a Cas9 encoding plasmid into a eukaryotic cell will result in the introduction of a
DSB in a sequence-specific manner at any desired locus adjacent to a PAM
sequence. A huge advantage of the CRISPR/Cas system is the ease with which
gRNAs can be designed and used to effectively target a diverse array of
sequences. Additionally, the gRNA is a relatively short oligonucleotide (usually ~
100bp), thus CRISPR/Cas gene targeting is generally more affordable than ZFN
or TALEN mediated gene targeting. However, as CRISPRs do not have any of
the specificity requirements built into the ZFN and TALEN architecture such as
the binding requirement on opposite strands or the use of obligate heterodimeric
nuclease domains, there remain concerns regarding their genome-wide
specificity.
V. Project goal I - Therapeutic applications of ZFNs to treat HIV
	
  

To date, ZFNs, TALENs and CRISPR/Cas nucleases have been used to

effectively target diverse genetic loci in cell lines and primary cells (including
stem cells) (5,14-23). One of the earliest therapeutic applications of designer
nucleases was the inactivation of a gene required for HIV infection in HIV6	
  	
  
	
  

susceptible CD4 T cells (14). To infect a cell, HIV must first bind to its primary
receptor CD4, and then to one of two coreceptors—CCR5 or CXCR4. As
individuals with a naturally occurring inactivating mutation in ccr5 are highly
resistant to HIV infection, this study attempted to replicate this phenotype by
inactivating the ccr5 gene using ZFNs and showed that these gene-modified cells
were both resistant to HIV infection and were selected for in the presence of
viruses that use CCR5 to enter cells (14). This promising preclinical data led to
one of the first human clinical trials involving a designer nuclease—the study of
the autologous transfer of CCR5-ZFN modified CD4 T cells in HIV infected
individuals (www.clinicaltrials.gov; Trial identifiers NCT00842634, NCT01044654,
NCT01543152). While this trial holds great promise for a novel HIV treatment
and a potential cure, if successful it would likely be most effective in patients that
harbor viruses that exclusively use CCR5 to infect cells. As up to half of HIVinfected individuals harbor viruses capable of using CXCR4 to infect cells (24), I
sought to make this therapeutic application of ZFNs more broadly applicable in
the first part of my thesis by using ZFNs to simultaneously inactivate both ccr5
and cxcr4 in primary human CD4 T cells (Chapters 2 and 3).
VI. Project goal II – Identification and characterization of sites of genomewide designer nuclease off-target activity
Although designer nucleases have the potential to change the way we
treat diseases and perform research, we do not yet have a complete
understanding of the genome-wide specificity of these nucleases or all the
7	
  	
  
	
  

factors that influence cleavage activity at unwanted sites. A number of studies
have shown that while each designer nuclease exhibits a high level of cleavage
activity at their target site, there is some level of unwanted cleavage activity at
off-target sites. By searching the genome for sites with sequence similarity to the
nuclease target site and analyzing these potential off-target sites for evidence of
nuclease activity, several studies have identified some sites of off-target
activity(14,15,25). However, while sequence similarity is likely a predictor of offtarget activity, there is mounting evidence suggesting that it is not the sole
predictor of off-target activity (26). Additionally, there are currently no studies
comparing the specificity of the three main classes of designer nucleases. Hence
as part of my thesis, I attempted to identify sites of off-target activity for the three
main classes of designer nuclease using a novel high-throughput assay to detect
genome-wide translocations involving nuclease-induced double strand breaks
(Chapter 4).
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Chapter 2. Searching for a cure: HIV infection and novel treatment
strategies
I. The HIV epidemic: A persistent problem
Since its identification as the etiologic agent of acquired immune
deficiency syndrome (AIDS), human immunodeficiency virus (HIV) has claimed
the lives of millions around the world. The introduction of antiretroviral therapy
(ART) for HIV infection has dramatically altered the course of the HIV pandemic
by delaying the progression to AIDS and increasing the lifespan of infected
individuals (27-30), while decreasing HIV transmission rates (31-34). However,
the prospect of eradication remains a distant one, as there are still 34 million
people living with HIV worldwide, and more than 2 million new infections every
year. Additionally, as the HIV infected population ages, we are learning that
control of HIV infection by ART does not completely restore health (reviewed in
(35)). Patients on ART remain at increased risk of developing cardiovascular
disease compared to age-matched uninfected controls (36), and HIV infection
also significantly increases the risk of developing kidney disease, osteoporosis,
and a number of non-AIDS defining malignancies, even when patients are well
controlled on ART (37-40). Moreover, ART itself is not without side effects, as
certain classes of antiretroviral drugs directly contribute to some of these
comorbidities. These HIV-associated morbidities that persist despite ART, the
high cost of ART, and the requirement for daily adherence to ART to control
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infection, all highlight the pressing need for strategies to achieve drug-free
control and an eventual cure for HIV.
II. Barriers to a cure: The HIV reservoir
The major obstacle to achieving a cure stems from the fact that HIV not
only infects and kills cells involved in combating infection (CD4 T cells), but also
establishes a stable reservoir in these cells that goes undetected by the immune
system (41-44). This latent reservoir is present in resting memory CD4 T cells, is
largely unaffected by ART, and is responsible for the rapid rebound in viremia
following ART cessation (43-47). As such, elimination of the reservoir is likely
required for a cure. Based on our understanding of HIV latency, it has long been
thought that reactivation of the latent reservoir would result in the detection of
infected cells and their subsequent destruction by the immune system. The
pursuit of this “shock-and-kill” approach has led to the identification of
pharmacologic compounds capable of reactivating latent HIV in vitro (reviewed in
(48)), and there is evidence that one such drug, the histone deacetylase inhibitor
vorinostat, is capable of disrupting HIV-1 latency to some degree in HIV infected
individuals on ART (49). However, a recent study by Shan et al showed that
following drug-induced reactivation of latency in CD4 T cells from patients on
ART, these cells were not killed by autologous cytotoxic lymphocytes (CTLs),
due to defects in the quality of the HIV-specific CTL response in ARTexperienced patients (50). These results suggest that pharmacologic reactivation
of latency alone may not be enough to eliminate the reservoir. As such, there is a
10	
  
	
  
	
  

need for alternative or complementary approaches that will enhance the ability of
the immune system of HIV-infected persons to identify and kill cells harboring
reactivated viruses if we hope to effectively eliminate the HIV reservoir using this
strategy. A recent landmark study by Ho et al has also called into question our
previous estimates of the HIV reservoir, and the ease with which the reservoir
can be reactivated (51). This work stemmed from the observation that DNA
measurements of the HIV reservoir size are up to 2-logs higher than
measurements obtained using the standard viral outgrowth assay—an assay that
estimates the reservoir size by measuring HIV production following maximum in
vitro T cell activation of resting CD4 T cells from HIV-infected individuals (52).
This difference in reservoir size estimates was initially believed to represent
defective proviruses—a belief supported by the error-prone nature of HIV
replication (53-58). However, a careful characterization of these uninduced
proviruses by Ho and colleagues revealed that up to 12% of them are actually
genetically intact, integrate into active sites of transcription, and when
synthesized, display replication kinetics comparable to those of latent viruses
induced by T cells activation. This study has 2 major implications for the shockand-kill approach and the HIV cure field in general—the replication-competent
HIV reservoir is considerably larger than previously thought, and reactivation of
latent HIV is not determined solely by the activation state of a T cell, but may in
fact be in part a stochastic process.
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III. Gene therapy for a cure
Genetic manipulation of long-lived primary CD4 T cells and hematopoietic
stem cells (HSCs) to prevent HIV infection has long been viewed as a viable
means of achieving ART-free control of infection, and following the recent report
of a cure for HIV (59,60), there has been a surge of interest in exploring gene
therapy-based approaches to treat HIV. This cure was achieved following an
allogeneic hematopoietic stem cell transplant (HSCT) to treat leukemia in an HIVinfected man, and was performed using cells from a donor bearing an
inactivating mutation in both copies of the C-C chemockine receptor type 5
(CCR5) gene—whose protein product is the primary HIV entry coreceptor
(59,60). This mutation—known as ccr5∆32—confers resistance to HIV infection
in homozygotes, and delays the progression to AIDS in heterozygotes (61-63).
Following the transplant, the patient was taken off ART and in the ensuing years
has remained free of HIV, with undetectable viral loads and substantial
decreases in HIV-specific antibodies, suggesting that a cure has indeed been
achieved. However, there remains a great deal of speculation regarding the
reason for the cure. One possible explanation is that the complete donor
chimerism achieved following allogeneic transplantation of CCR5-negative cells
simply created an environment incapable of supporting HIV infection by
eradicating all cells susceptible to infection with CCR5-using HIV. However, this
may not fully explain the observed cure as the patient in question also had low
levels of HIV capable of entering cells in a CCR5-independent manner by using
the other HIV coreceptor C-X-C chemokine receptor type 4 (CXCR4), and yet
12	
  
	
  
	
  

these viruses failed to expand following the transplant. That such viruses can
expand in vivo in the face of selective pressure against CCR5 is evidenced by
the fact that the most common cause of virologic failure following treatment with
the CCR5 antagonist maraviroc is outgrowth of pre-existing CXCR4-using HIV
strains (64,65). As such, alternative explanations for the cure including the role of
graft-vs-host-disease (GVHD) in clearing the infection have been considered,
with the assumption that the development of GVHD following the transplant led to
the detection and donor cell-mediated clearance of all host immune cells
including those cells harboring the latent HIV reservoir. Another potential reason
for this remarkable cure is the destruction of the HIV reservoir by the conditioning
chemotherapy and total body irradiation administered prior to the transplant.
While such transplants have been performed in HIV infected patients in the past
with no effect on their HIV infection, recent evidence suggests that allogeneic
stem cell transplants with CCR5-positive cells may in fact have an effect on the
size of the HIV reservoir as measured by the viral outgrowth assay(66).
The striking resistance to HIV infection observed in ccr5∆32 homozygotes
and the recent report of a cure following HSCT using ccr5∆32 cells has spurred
several gene therapy efforts to block HIV infection at the level of entry in an
attempt to reproduce this HIV-resistant phenotype in individuals lacking the
delta32 mutation. As a result, several promising preclinical studies have
successfully provided some form of protection against HIV by targeting infection
at the level of entry and a number of these studies have been advanced to
human clinical trials (Table 1).
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IV. HIV Entry: The Basics
The HIV life cycle begins with entry of the virus into susceptible cells. To
enter a cell, HIV must first bind to its primary receptor CD4, and then to one of
two coreceptors—CCR5 or CXCR4 (Figure 1) [5-13]. The choice of coreceptor
used by the virus is intimately linked to disease acquisition and pathogenesis as
the majority of transmitted viruses use CCR5 to enter cells [14-17], while the
appearance of viruses capable of using CXCR4 during infection is associated
with a more rapid progression to AIDS [18-21].
Entry of HIV into target cells is mediated by the type I integral membrane
viral glycoprotein Env. Env is synthesized as a polypeptide precursor termed
gp160 which undergoes several of modifications within the cell as it is
transported to the cell surface, including extensive N-linked glycosylation, and
cleavage by cellular proteases into the extracellular gp120 and the membranespanning gp41 subunits [27-29]. The extensive glycosylation of Env contributes
to its ability to evade humoral immune responses, as the carbohydrate moieties
covering its surface are poorly immunogenic and may shield potentially antigenic
epitopes on the glycoprotein from recognition by the immune system [30-32].
Following gp160 cleavage—an event required for subsequent membrane
fusion—gp120 and gp41 maintain their association via non-covalent interactions
and are transported to the cell surface where they exist as a trimer of
heterodimers that is ultimately incorporated into the viral membrane. Prior to CD4
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binding—the first essential step in HIV entry—a number of cell-surface molecules
are capable of mediating Env-dependent attachment of the virion to target cells.
One such attachment factor is the C-type lectin CD209 or dendritic cell-specific
intercellular adhesion molecule (ICAM) grabbing non-integrin (DC-SIGN).
Expressed on dendritic cells, DC-SIGN and several other lectins are capable of
binding Env and boosting infection in vitro by facilitating trans-infection of
surrounding CD4 T cells by dendritic cell-bound virions (reviewed in [33]). More
recently, monomeric gp120 from some HIV strains has been shown to bind the
gut homing integrin α4ß7 [34,35], which is expressed on activated CD4 T cells.
This finding is of particular interest as the depletion of CD4 T cells in the gutassociated lymphoid tissue (GALT) early in infection is a hallmark of HIV disease
[36-38] and ß7 integrins mediate trafficking of lymphocytes to the gut mucosa
[39]. However, it is not clear whether α4ß7 supports binding of trimeric Env on
the surface of virions, and thus its relevance to the gut pathology associated with
HIV infection remains unknown. Furthermore, while interactions with these and
other attachment factors influence HIV infection in vitro, little is known regarding
their significance in vivo.
The gp120 subunit of Env is composed of five relatively conserved (C1 –
C5) and five more variable (V1 – V5) regions [40]. The conserved regions form
the proximal core of gp120 while intrachain disulfide bonds in the variable
regions of gp120 result in the formation of five variable ‘loop’ structures that
make up the most exterior portion of the gp120 ectodomain [41]. The CD4
binding site on gp120 is a well conserved cavity formed at the interface of the
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inner and outer domains of the glycoprotein [42]. Following binding of gp120 to
CD4, a series of conformational changes occur including the rearrangement of
two pairs of ß-sheets from the gp120 inner and outer domains that come together
to form a four-stranded ß-sheet structure termed the bridging sheet. The bridging
sheet links the inner and outer domains of gp120 and interacts with the viral
coreceptor, be it CCR5 or CXCR4 [42,43]. gp120 binding to CD4 also results in
enhanced exposure and reorientation of the V1/V2 and V3 loops of gp120,
outward rotation of each gp120 monomer to reveal the gp41 stalk, and hinge-like
movements in CD4 that are thought to bring the viral membrane in close
proximity to the target cell [42,44,45]. Together, all of these events culminate in
the creation and exposure of the coreceptor-binding site.
The HIV coreceptors belong to the family of chemokine receptors—seventransmembrane G-protein coupled receptors with prominent roles in immune cell
trafficking. These receptors have three extracellular and intracellular loops,
extracellular N-termini, and intracellular C-termini. While several different
chemokine receptors are capable of mediating HIV entry in vitro, current
evidence suggests that the CCR5 and CXCR4 chemokine receptors are the most
frequently utilized in vivo [46-48]. Viruses capable of utilizing CCR5 alone,
CXCR4 alone, or both coreceptors, are labeled R5-tropic, X4-tropic, and RX54 or
dual-tropic viruses respectively. CCR5 is the primary coreceptor for the majority
of HIV-1 isolates and is expressed on CD4 T-cell subsets, macrophages and
dendritic cells, while CXCR4 is less commonly used, but is expressed on a wide
variety of cells both within and outside the immune system [49]. For reasons that
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remain unclear, the majority of transmitted viruses utilize CCR5 irrespective of
the route of transmission and despite the availability of target cells expressing
CXCR4 [17,50,51]. Multiple lines of evidence including mutational analyses,
studies of small molecule inhibitors, and inhibition by coreceptor-specific blocking
antibodies suggest that both the second extracellular loop (ECL2) and sulfated
tyrosines within the N-terminus of the coreceptors interact with the V3 loop of
gp120 and mediate coreceptor binding [52-57]. The V3 loop is also known to be
a key determinant of coreceptor preference as the presence of positively charged
amino acids at positions 11 and or 24/25 of V3 is correlated with CXCR4 usage
[58,59].
The HIV fusion machinery is contained within the gp41 subunit of Env,
which is comprised of a large cytoplasmic domain, a membrane-spanning
segment, and an ectodomain that maintains contact with gp120. The ectodomain
contains a typical fusion peptide—a stretch of hydrophobic amino acids at the Nterminus [60,61]—along with two α-helical heptad repeats (HR), the N-terminal
HR1 and the C-terminal HR2 repeats [62,63]. The current model of gp41mediated fusion is based on studies performed using HIV fusion inhibitors,
crystal structures, and structural similarities between gp41 and other wellcharacterized type I membrane fusion proteins including the influenza virus
glycoprotein, hemagglutinin (HA) [63-66]. In this model, the sequential interaction
of Env with CD4 and a coreceptor results in exposure of the fusion peptide,
which then inserts into the plasma membrane of the host cell, causing gp41 to
physically link both membranes. Subsequently, the three HR1 domains of the
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Env trimer interact with one another to form a coiled coil, and the three HR2
segments fold back on the HR1 trimer creating a six-helix bundle that brings the
viral and host cell membranes in close contact with one another, allowing for
mixing of the two membranes and formation of the fusion pore. Fusion between
Env and the host cell was long thought to occur at the plasma membrane as HIV
entry occurs in a pH-independent manner [67] and Env is capable of mediating
fusion between neighboring cells, provided that they express CD4 and an
appropriate coreceptor [68]. However, recent work using trans dominant-negative
mutants of proteins involved in clathrin-mediated endocytosis [69] along with
elegant studies using single-virion imaging [70] have demonstrated a clear role
for components of the endocytic pathway in HIV entry in a number of cell lines.
These studies were performed using immortalized cell lines, and as such, the
role of the endocytic pathway in HIV entry into relevant cell types in vivo is yet to
be determined.
The cure achieved following allogeneic HSCT using ccr5∆32 cells
highlights how our understanding of a very basic question—how a virus enters its
host cell—has led to the development of new antiviral drugs and therapeutic
approaches that have brought us a step closer to controlling the global HIV
pandemic.
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VI. Pharmacologic inhibition of HIV entry
The multi-step process by which HIV enters cells provides a series of
unique targets for interventions to prevent viral entry including receptor and
coreceptor binding, and membrane fusion. Efforts to inhibit these steps have led
to the discovery of a new class of anti-HIV drugs—the HIV entry inhibitors
(reviewed in [71]). A number of CCR5 inhibitors have been developed and
display anti-HIV activity both in vitro and in vivo. These drugs are believed to
work by binding to CCR5 at a site distinct from the gp120-binding site and
subsequently alter the conformation of the CCR5 extracellular loops required for
entry of R5-tropic HIV variants. One such CCR5 antagonist, maraviroc, is
licensed for use in the United States and in Europe [43,72]. A variety of CXCR4
antagonists have also been developed, and while they exhibit potent anti-HIV
activity in vitro (against X4 but not R5 virus strains), administration of these drugs
in vivo results in mobilization of HSCs from the bone marrow to the peripheral
blood, highlighting the important role of CXCR4 in HSC homing [73-75]. Although
this side effect limits their use in HIV-infected individuals, the CXCR4 antagonist
plerixafor, is currently used to mobilize HSCs for subsequent autologous transfer
in patients with non-Hodgkin’s lymphoma and multiple myeloma [76].
gp41-mediated membrane fusion presents another drug target in the HIV
entry process. Synthetic peptides based on the sequence of HR2 display
significant antiviral activity against HIV in vitro but for many years, the
mechanism of this antiviral activity remained unknown [77]. However, the
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observation that these peptides display higher antiviral activity as dimers and the
elucidation of the structure of the gp41 fusion machinery have led to a model for
their mechanism of action [63,64,78]. These drugs are now believed to act in a
dominant negative fashion by competing with the HR1 and HR2 domains of gp41
and ultimately preventing the formation of the six-helix bundle required for
membrane fusion. One such peptide, enfuvirtide, is the only FDA-approved HIV
fusion inhibitor, and is indicated for use in combination with standard
antiretroviral therapy. However the twice-daily subcutaneous dosing schedule of
the drug makes it an unattractive choice for many patients and care providers.
As is the case for most anti-HIV drugs, viral variants resistant to all of the
entry inhibitors have been identified. The appearance of maraviroc resistant
viruses in vitro is a well-established phenomenon and these viruses either adapt
to recognize the drug-bound conformation of CCR5, or more commonly, acquire
the ability to use CXCR4 in addition to CCR5 (reviewed in [79]). In vivo,
resistance to maraviroc most commonly results from outgrowth of pre-existing X4
or R5X4 variants that are sometimes present at very low levels prior to the onset
of therapy. As such, tropism testing is indicated prior to administration of
maraviroc. In the case of enfuvirtide, mutations within HR1 and HR2 rapidly
select for viruses with a dramatically decreased sensitivity to the drug [80,81].
HIV drug resistance is not unique to entry inhibitors, but is a widespread problem
seen with all classes of HIV chemotherapeutics, and while ART increases
survival in HIV-infected individuals, the problems of drug resistance, impaired
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immune function despite ART, long-term financial cost and drug-associated
toxicities of ART continue to fuel the search for curative therapies for HIV
infection.

VII. HIV entry as a target for gene therapy
To date, several studies have explored genetic approaches to hijack or
halt the 3 main steps of HIV entry—CD4 binding, coreceptor binding and
membrane fusion. Outside of its role as the primary receptor for HIV, CD4 plays
a critical role in antigen recognition by the T-cell receptor and as such,
abrogation of CD4 expression is not a viable option to prevent HIV entry. A
number of early gene therapy studies, however, took advantage of the fact that
HIV-1 requires CD4 to enter cells, and coupled the extracellular and
transmembrane domains of CD4 to the intracellular signaling domain of the
invariant ζ-chain of the T cell receptor (TCR) thus pairing viral recognition by CD4
with TCR signaling and downstream effector functions. Introduction of these
chimeric receptors into CD4 and CD8 T cells resulted in HIV-specific targeting by
both cell types in vitro. In particular, expression of these chimeric TCRs in
cytotoxic CD8 cells allowed them to recognize and kill HIV infected cells which
often express Env on their surface (67,68). Following these promising preclinical
studies, two clinical trials investigated the effects of adoptive transfer of chimeric
TCR modified CD4 and CD8 T cells on HIV infection. In both trials, the genemodified cells successfully engrafted and trafficked to the rectal mucosa—a
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major site of HIV replication (69-71). While neither study observed a significant
decrease in the viral load of treated subjects, one study reported a trend towards
a decrease in reservoir size following treatment with the gene-modified cells(71).
To date, most gene therapy attempts to inhibit HIV entry have focused on
interfering with the interaction between the virus and its coreceptors by either
reducing or eliminating coreceptor expression. When attempting to genetically
modulate coreceptor expression, an important consideration is the choice of cells
to be treated as the ease with which target cells can be modified, and their
longevity and capacity for self-renewal all influence the chances of success
(reviewed in (72)). For this reason, most studies have focused on modifying
either T cells or CD34+ HSCs with the eventual goal of adoptive transfer of the
gene-modified cells. CCR5 is a particularly attractive target for HIV entry-focused
gene therapy as the complete loss of CCR5 expression appears to be well
tolerated in ccr5∆32 homozygotes. Additionally, the CCR5 small molecule
antagonist maraviroc, which is currently approved for use in HIV infected
patients, exhibits potent antiviral activity without adversely affecting immune cell
function, suggesting that a partial or complete loss of CCR5 may not result in
severe immunologic consequences (64,65). On the other hand, less is known
about the potential consequences of decreasing or completely ablating CXCR4
expression. In particular, CXCR4’s role in the bone-marrow retention of HSCs
(73) may result in the unintended side effect of HSC egress from the bone
marrow into the peripheral blood.
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A number of studies have demonstrated the ability of exogenous
transgenes to target the HIV coreceptors at the level of protein, RNA or DNA,
with the final common result being decreased surface coreceptor expression.
Early work using a CCR5-specific single-chain antibody engineered to express
an ER-retention motif showed that these “intrabodies” prevented trafficking of the
CCR5 protein to the cell surface. When introduced into susceptible cells, the
resulting intrabody-mediated intracellular sequestration of CCR5 resulted in a
decrease in infection by CCR5-using HIV (74,75). RNA-based approaches have
also provided promising results—multiple studies have used RNA interference,
CCR5-targeted ribozymes or a combination of both to efficiently decrease levels
of CCR5 mRNA and thus surface expression of CCR5 (76-82). A recent clinical
trial examined the safety and potential efficacy of one such RNA-based agent by
following the adoptive transfer of autologous CD34+ stem cells transduced with a
lentivirus encoding a CCR5 ribozyme, an anti-HIV siRNA and an RNA decoy that
prevents initiation of HIV transcription (83). In this study, the gene-marked cells
engrafted successfully, and multiple hematopoietic lineages expressing the
transgene were detectable for up to two years post-infusion. However, these
cells did not provide any observable clinical benefit in terms of CD4 count or HIV
viral load. While the lack of clinical benefit was likely in part due to the low
percentage of gene-marked cells infused (~0.14% of infused cells were genemarked on average), another potential problem with this and other RNA-based
gene therapy approaches to decrease CCR5 expression is their inability to
completely and permanently eliminate surface CCR5 expression. This poses a
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problem, as many HIV-1 isolates are capable of using low surface levels of
CCR5 to enter cells. For this reason, many groups have begun exploring
permanent modification of the host genome using designer nucleases so as to
completely eliminate surface CCR5 expression.
CCR5-specific ZFNs are capable of permanently inactivating the CCR5
gene in primary CD4 T cells, and ZFN-modification confers a survival advantage
on gene-modified cells in the presence of CCR5-using HIV both in vitro and in a
humanized mouse model of HIV infection (14). Additionally, ZFN modification of
CCR5 in primary CD34+ HSCs results in the production of multiple hematopoietic
lineages all lacking surface CCR5 expression (21). As a result of these promising
preclinical data, several clinical trials are currently investigating the safety and
efficacy of autologous transplants using ZFN-modified CD4 T cells or CD34+
HSCs in HIV infected individuals (www.clinicaltrials.gov; Trial identifiers
NCT00842634, NCT01044654, NCT01543152). While these strategies are
capable of generating cells that are highly resistant to infection with CCR5-using
HIV, they offer no protection against viruses that use CXCR4. To this end, a
recent study showed the ability of a ZFN pair targeting the CXCR4 coreceptor to
specifically and efficiently inactivating this coreceptor in primary human CD4 T
cells and in a humanized mouse model of HIV infection(15). However, in this
study, protection of CD4 T cells in animals harboring CXCR4-modified cells was
only transient, due to the outgrowth of viruses capable of using CCR5 to infect
cells. These results, and the emergence of CXCR4-using HIV in patients who fail
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treatment with the CCR5 antagonist maraviroc, highlight the importance of
preventing both CCR5- and CXCR4-mediated entry in order to completely
abolish infection by the two major HIV variants.
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Chapter 3. Simultaneous zinc-finger nuclease editing of the HIV
coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection

Contributors to this work include Craig B. Wilen (UPenn), Jianbin Wang
(Sangamo Biosciences), Jennifer Duong (Sangamo Biosciences), Anthony J
Secreto (UPenn), Gwenn A. Danet-Desnoyers (UPenn), James L. Riley (UPenn),
Phillip D Gregory (Sangamo Biosciences), Carl H. June (UPenn), and Michael C.
Holmes (Sangamo Biosciences).

I. Statement of hypothesis
I hypothesize that the simultaneous inactivation of ccr5 and cxcr4 in T cell
lines and primary human CD4 T cells is feasible. Additionally, I hypothesize that
cells lacking both CCR5 and CXCR4 will have a survival advantage in the
presence of both CCR5 and CXCR4-using HIV in vitro. Finally, I hypothesize that
humanized mice bearing these double-gene modified cells will be better able to
maintain their CD4 counts in the face of HIV-1 challenge as compared to wildtype mice, or mice lacking a single coreceptor.

II. Materials and methods
Cell culture and ZFN treatment. SupT1 T cells expressing multiple copies of
CCR5 introduced by lentiviral transduction (SupT1-R5), and primary human
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CD4+ T cells were maintained in RPMI growth media (Invitrogen) supplemented
with 10% fetal bovine serum (FBS). CD4+ T cells were grown in the presence of
human interleukin 2 (IL-2) (100 IU/ml). We used CCR5 (R5) and CXCR4 (X4)
zinc finger proteins (ZFPs) from our previous studies(14,15). However, the ZFN
nuclease domains were the ELD/KKR variant which were modified to function as
obligate heterodimers with enhanced cleavage activity(84). To deliver ZFNs, we
simultaneously transduced cells with two Ad5/F35 vectors encoding either the
R5- or X4-ZFNs, or an Ad5/F35 GFP-expressing control vector(14,15). This is a
chimeric adenoviral vector based on the AdEasy vector system (Promega) with
an E1/E3 deleted backbone and a chimeric fiber gene comprised of a serotype 5
fiber tail domain, and serotype 35 shaft and knob domains(85). CD4+ T cells
were activated 18-24 hours prior to vector transduction with anti-CD3/anti-CD28
coated magnetic beads(15) . We determined vector multiplicities of infection
(MOIs) using the 293T cell line and measured mutation frequencies by surveyor
nuclease (Cel1) or T7 Endonuclease I assay (T7E1), or deep
sequencing(22,86,87).

Virus production and infection. Pseudoviruses mediate one round of infection
as the viral glycoprotein gene is only supplied in trans. We generated HIV
pseudoviruses encoding a GFP reporter, bearing either the HIV glycoprotein
(Env) or the Vesicular Stomatitis Virus glycoprotein (VSV–G) by co-transfection
of the viral glycoprotein and the pNL4.3-Δenv-vpr+-eGFP-HIV backbone(88) into
293-T cells using calcium phosphate. We harvested supernatants after 72 hours
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and concentrated virus by ultracentrifugation(89). The HIV pseudoviruses were
made using the R5 and X4-HIV envs JRFL and TYBE(90) respectively. For
SupT1-R5 pseudovirus infections, we infected 1x105 cells in a 96-well v-bottom
plate with 500ng of HIV-1 p24 or 5-10ng of HIV-VSV-G p24. Samples were spun
at 1200xg for 90 minutes at 25°C then transferred to 37°C. Infection was
measured at 96-hours by flow cytometric analysis of GFP positive cells.
Replication competent HIV-1 was made in primary CD4+ T cells (89) and
we infected SupT1-R5 cells and primary cells with 50-100ng p24 per million cells
5-7 days following ZFN treatment. The replication competent HIV-1 strains used
were the R5-virus BaL, and the X4-viruses BK132 and HxB2. All CD4+ T cell
infections were performed using cells from three independent donors. For all
infections where cells were challenged simultaneously with R5 and X4-HIV, the
viruses were mixed in a 1:1 ratio normalized by HIV-1 p24.

Flow cytometry. Cells were stained at room temperature in Fluorescenceactivated cell sorting (FACS) buffer (PBS-/-, 2% FBS, 2mM EDTA). SupT1-R5
cells and CD4 T cells were stained with Live/Dead Aqua and QD655-CD3 (clone
S4.1) (Invitrogen), Fluorescein isothiocyanate(FITC)-CD45 (clone H130)
(Biolegend), AlexaFluor700-CD4 (clone RPA-T4), PacificBlue-CD8 (clone RPAT8), Allophycocyanin (APC)-CCR5 (clone 2D7) and Phycoerythrin (PE)-CXCR4
(clone 12G5) (BD Biosciences). Samples were run on an LSR II (BD
Biosciences), and analyzed using FlowJo 10.0.4 (Treestar).
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HIV-1 humanized mouse challenge.
12-14 week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj (NSG) immunodeficient mice
received either unmodified CD4 T-cells, R5-ZFN-treated CD4 T-cells, or R5/X4ZFN-treated CD4 T-cells. Each group contained 18 animals and each animal
received 1.8x107 cells. Mice were randomly assigned to control for cage, sex and
birth cohort effects. The animals were maintained in a defined flora facility at the
University of Pennsylvania, with approval of the Institutional Animal Care and
Use Committee. We measured peripheral blood CD4 counts 21 days postinfusion to assess engraftment by staining for CD45+/CD3+/CD4+/CD8- cells.
Three days later, half the animals in each group received 5x104 CD4+ T-cells
infected with the R5-virus BaL, and 5.0x104 CD4+ T-cells infected with the X4virus Bk132. Control animals received 1x105 uninfected CD4+ T-cells. We
performed retro-orbital bleeds to assess CD4 counts and measure gene
disruption. Mice were euthanized following the development of xenogeneic-graftversus-host-disease. Cardiac punctures and splenectomies were performed on
all mice following euthanasia. We passed spleens through a 70µm strainer to
obtain a single-cell suspension for measuring gene modification and CD4 count.
ZFN-induced mutation frequencies were determined by performing deep
sequencing at the R5 and X4-ZFN target sites(22).

Off-target site analysis. We previously used systematic evolution of ligands by
exponential enrichment (SELEX) to determine the in vitro binding preference of
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each zinc finger protein (ZFP)(14,15). Using the information on CCR5 and
CXCR4 binding preferences, we generated a position-weight matrix which we
aligned to the human genome to look for sites with similarity to each of the four
possible combinations of CCR5-CXCR4 cross heterodimers (R5-left with X4right; R5-left with X4-left; R5-right with X4-right; R5-right with X4-left). We
allowed up to a 4bp mismatch compared to the SELEX consensus sequence,
and considered sites with a 5bp or 6bp spacer between each ZFP pair. We
performed deep sequencing at these sites to identify off-target activity(22). Offtarget activity was defined as an insertion/deletion (indel) involving the target
region (20 bp) centered at the nuclease binding sites at a frequency of greater
than 0.1%, and with a calculated ratio of cleavage (Z-M)/M of greater than 2,
where Z represents % indels in ZFN treated samples, and M represents % indels
in mock treated samples.

III. Results
Simultaneous ZFN disruption of ccr5 and cxcr4 in a T-cell line protects
from R5 and X4-HIV infection
To determine whether two ZFN pairs targeting the HIV-coreceptors ccr5
(R5) and cxcr4 (X4) could abolish expression of both coreceptors, we cotransduced the human SupT1-R5 T-cell line with increasing amounts of the
Ad5/F35 vectors encoding the R5-ZFN and X4-ZFN. Co-administration of both
(R5/X4) ZFNs caused a dose-dependent reduction in cell surface expression of
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both coreceptors with 9% of cells no longer expressing either coreceptor at the
highest MOI, while delivery of the same vector encoding GFP had no effect on
surface R5 or X4 levels (Figures 3A-B). Next, we assessed the ability of ccr5
and cxcr4 co-disruption to protect cells from infection with R5 and X4-using HIV-1
strains. We challenged untreated or R5/X4-ZFN treated SupT1-R5 cells
simultaneously with the R5- and X4-HIV strains BaL and BK132 respectively and
monitored surface coreceptor expression for 42 days. The proportion of double
(R5/X4) negative cells increased over the course of the infection such that by 25
days post-infection, 96–99% of the R5/X4-ZFN treated cells challenged with HIV
no longer expressed either coreceptor (Figure 3C-D). In contrast, the proportion
of double-negative cells in the uninfected R5/X4-ZFN treated group did not
change significantly over this time (Figure 3C, top panels). We also monitored
cell viability and while untreated cells all died by ten days post-infection, a portion
of the R5/X4-ZFN treated cells survived the infection with cell numbers
increasing exponentially over time (Figure 3E). The coreceptor negative cells that
survived HIV infection were re-challenged with pseudovirus bearing either HIV
Env or VSV-G to confirm that the mechanism of resistance was due to inhibition
of HIV Env-specific entry. These cells were highly resistant to either R5 or X4HIV pseudovirus re-challenge, displaying 170-fold and 92-fold decreases in
reinfection with R5- and X4-HIV respectively (Figure 3F). Of note, low levels of
residual infection (~0.1%) were observed in the R5/X4-ZFN group pre-challenged
with HIV. However, the majority of this residual infection occurred in the 1-4% of
cells still expressing CCR5 and CXCR4 (data not shown). Additionally, these
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coreceptor negative cells were readily infected by HIV expressing the vesicular
stomatitis virus glycoprotein (VSV-G HIV), a virus that is not dependent upon R5
or X4 for infection (Figure 3F). Taken together, these data suggest that
simultaneous delivery of two ZFN pairs is an efficient and viable strategy to
disrupt ccr5 and cxcr4, resulting in cells resistant to infection with both R5 and
X4-using HIV.

ZFNs achieve simultaneous disruption of ccr5 and cxcr4 in human CD4+ T
cells
To determine the feasibility of this approach in primary cells, CD4+ T cells from
healthy human donors were simultaneously transduced with the adenoviral
vectors encoding the R5 and X4-ZFNs. Transducing cells with MOIs of up to 500
of each ZFN resulted in modification of approximately 20% of all R5 and X4
genes as measured by the Cel1 assay, without significant impact on cell growth
compared to untransduced controls (Figure 4A-B). As surface expression of
CCR5 is undetectable on most primary CD4+ T cells, we could not determine the
proportion of cells lacking both coreceptors by flow cytometry. To exclude the
possibility that co-administration of both ZFNs in primary cells results in R5 and
X4 gene modification in mutually exclusive cells, we delivered both ZFNs to
CD4+ T cells and sorted them by FACS based on surface CXCR4 expression
into CXCR4-high and CXCR4-low populations (Figure 4C). We then measured
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levels of R5 and X4 gene modification in both of these populations. While cxcr4
gene modification was greatly reduced in the X4-high population following
sorting, levels of ccr5 modification were similar in the X4-high and X4-low
populations (Figure 4D), suggesting that adenoviral dual-ZFN treatment achieved
dual-modification of ccr5 and cxcr4 in primary CD4+ T cells.
Depletion of central memory CD4+ T cells is a hallmark of HIV pathogenesis and
progression to AIDS(91). As such, protection of this long-lived subset is important
for the success of any HIV gene therapy approach. We therefore determined
whether central memory CD4+ T cells could be modified by the R5- and X4ZFNs. We first transduced CD4+ T cells with both ZFNs, expanded them in vitro
for 10 days and then sorted the cells by FACS into central and effector memory
populations based on surface expression of the memory markers CCR7 and
CD45RO(92) (Figure 4E). CD4+ T cell activation using CD3/CD28 coated beads
results in differentiation of ~97% of cells into a memory phenotype, with roughly
half of all cells being either central or effector memory cells and the proportion of
effector and central memory subtypes is not affected by treatment with the
adenoviral vector or the ZFN (data not shown). We detected both ccr5 and cxcr4
modification (Cel1) in the central memory (CCR7+, CD45RO+) and effector
memory (CCR7-, CD45RO+) populations at similar levels (Figure 4E) suggesting
that we can effectively target the coreceptors in these critically important T cell
subsets.
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Survival advantage of dual-ZFN treated CD4+ T cells in vitro
To determine if the level of gene modification seen in primary cells rendered
them resistant to both forms of HIV-1, we treated CD4+ T cells with both ZFNs,
the R5-ZFN alone, or with a GFP control. We then challenged all three groups
with a mix of R5- and X4-using HIV-1 and monitored cell growth and viability. By
32 days post-infection, there were no detectable live cells in the groups that
received either no ZFN or the R5-ZFN alone, whereas cells from the R5/X4 ZFN
group continued to expand (Figure 5A). We measured levels of ccr5 and cxcr4
gene modification 3 weeks into the infection in the R5/X4-ZFN treated group and
observed increases in both ccr5 (1.8-fold) and cxcr4 (1.9-fold) gene modification
(Figure 5B-C) when compared to the start of the infection. The preservation of
cell growth and increases in gene modification seen only in the R5/X4-ZFN group
in the presence of HIV suggest that ZFN-modification of both coreceptors
provides a significant survival advantage in the presence of R5- and X4-using
HIV.

Analysis of off-target cleavage following dual ZFN administration
Simultaneous administration of two ZFN pairs creates the theoretical
possibility of forming four different ZFN cross-heterodimers made up of the left
and right halves of the two unique ZFN pairs. These ZFN cross-heterodimers
may subsequently bind to unintended target sites, resulting in more off-target
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gene modification compared to delivery of a single ZFN pair. As the target
sequence contributes to ZFN binding and thus specificity(93), we previously
determined the in vitro DNA binding preference of each CCR5 and CXCR4 ZFP
using SELEX(14,15). We constructed a position-weight matrix for each 12bp ZFP
binding site, and by comparing these sequences against the human genome to
identify potential off-target binding sites, identified sites that were in fact
independently cleaved by the R5- and X4-ZFNs(14,15). In this study, we took a
similar approach to identify off target sites that could result from the binding and
cleavage of a ZFN heterodimer consisting of one half R5-ZFN and one-half X4ZFN. We performed deep sequencing at these predicted sites in primary CD4+ T
cells following treatment with both the R5- and X4-ZFNs compared to otherwise
identical untransduced controls (Table 2). Using genomic DNA from samples
where on-target modification of ccr5 and cxcr4 were 28% and 20% respectively,
we analyzed 4,000-20,000 reads per predicted off-target site but failed to detect
significant levels of modification at any of the 40 predicted off-target sites (Table
2). These results suggests that cross-heterodimerization of the R5- and X4-ZFN
pairs following delivery to primary CD4+ T cells does not result in detectable offtarget activity, at the 40 sites examined. Moreover, the use of recently described
orthogonal heterodimeric nuclease domains that further restrict cleavage (94)
could further address this concern.
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Dual coreceptor disruption protects CD4+ T cells following HIV infection in
vivo
NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj (NSG) immunodeficient mice are a useful
model for studying HIV-1 in vivo as their immune systems can be reconstituted
using human cells that are susceptible to HIV infection(95). To assess whether
our approach protects against infection with both R5- and X4-HIV in vivo, we
treated primary CD4+ T cells with no ZFN, the R5-ZFN alone or with the R5- and
X4-ZFNs simultaneously. Three groups of 18 mice each were infused with
1.8X107 cells per animal from each treatment group (Figure 6A). We observed
CD4+ T cell engraftment across all groups 21 days post-infusion (Figure 6B). We
then infected half the animals in each group by simultaneously infusing 5x104
unmodified (no ZFN) CD4+ T cells infected with the R5-virus BaL and 5x104
unmodified CD4+ T cells infected with the X4-virus BK132. Of note, while the
BK132 HIV-1 swarm primarily uses CXCR4 to enter cells, it can also achieve
very low levels of infection using CCR5(96) as evidenced by the outgrowth of R5HIV when this virus was used to challenge X4-ZFN treated CD4 T cells(15). Prior
to infusion, the frequency of HIV p24+ cells was 58% and 44% in the R5 and X4HIV infected cells respectively. Control animals in each group received an
infusion of 1x105 uninfected, unmodified CD4+ T cells. Animals that received R5ZFN or R5/X4-ZFN treated cells had 5.5 and 12.8-fold lower CD4 counts
respectively, than animals that received untransduced cells when measured
three days prior to infection (Figure 6B). However, this difference in CD4 counts
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was no longer present at the time of the first peripheral blood sampling six days
post-infection (Figure 6D). This slight engraftment difference was not seen
previously (14,15) and may be donor specific. While CCR5 ablation alone was
previously shown to protect against challenge with CCR5-using HIV(14), animals
that received both ZFNs were better able to maintain their CD4+ T cell counts
following challenge with R5- and X4-HIV (Figure 6D). Specifically, CD4 counts in
animals from the infected R5/X4-ZFN group were 35 and100-fold higher than
those in animals from the mock and R5-ZFN infected groups respectively by 22
days post-infection, and these differences increased to an average 200-fold
difference 55 days post infection (Figure 6D). Additionally, we measured the
proportion of human CD4+ T cells in the spleens of infected animals at time of
sacrifice. In animals that received dual-ZFN treated cells, up to 10% of all cells
populating the spleen were human CD4+ T cells whereas we could not detect
any human CD4+ T cells in spleens from animals that received either no ZFN or
the R5-ZFN alone (Figure 6C).
To determine the mechanism of CD4 count maintenance observed in the
R5/X4-ZFN group, we performed deep sequencing at the ZFN cut-sites in CD4+
T cells from animals in the R5/X4-ZFN group to measure changes in the
proportion of ZFN-induced indels. There was no change in ccr5 or cxcr4 gene
modification in uninfected animals that received both ZFNs. However, on
average, 69% of all ccr5 genes and 73% of all cxcr4 genes were mutated in
CD4+ T cells from the infected R5/X4-ZFN animals by 34 days post-infection
37	
  
	
  
	
  

(Figure 7A). This represents a 2.2-fold increase in ccr5-modification and a 2.3fold increase in cxcr4-modification compared to six days post-infection.
Additionally, we observed significantly lower surface expression of both
coreceptors on cells from the infected R5/X4-ZFN treated mice 34 days postinfection (Figure 7B). These data provide strong evidence that simultaneous
disruption of ccr5 and cxcr4 using ZFNs is capable of generating a pool of cells
that are resistant to the major forms of HIV in vivo, and these cells can engraft,
traffic normally to the spleen, and have a significant survival advantage in the
presence of R5- and X4-using HIV.

IV. Discussion
Genetic approaches to control HIV infection have so far involved the
removal of host genes required by the virus, or the introduction of antiviral genes
that interfere with virus replication(72,97). While both are attractive options, the
latter approach could be hampered by the potential immunogenicity of foreign
transgenes and the diversity of the HIV viral quasispecies in chronically infected
individuals, which may allow for the outgrowth of viral variants resistant to these
antiviral genes. Removal of essential host factors such as the coreceptors, may
present a greater challenge for the virus to overcome as suggested by the
natural HIV resistance in ccr5∆32 homozygotes and the functional cure achieved
following the transplantation of ccr5∆32 stem cells(59,60). Genetic editing
through the use of coreceptor-specific ZFNs clearly renders a fraction of cells
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coreceptor-negative, as HIV-1 challenge of ZFN-treated cells results in
preferential survival of edited cells lacking the targeted coreceptor(14,15).
Treatment with R5-specific ZFNs results in permanent modification of 30% and
50% of ccr5 alleles in human hematopoietic stem cells and T cells
respectively(14,22), with a bi-allelic modification frequency of up to half of
that(22). The efficiency of bi-allelic disruption becomes even more important
when attempting to disrupt both ccr5 and cxcr4, necessitating the inactivation of
four genes in a given cell to render it resistant to infection by virtually all HIV-1
strains.
Individuals lacking ccr5 do not display severe phenotypic abnormalities
and its pharmacologic blockade is well tolerated(64), making it an ideal target for
permanent modification. However less is known about the effects of the specific
loss of CXCR4 expression on CD4+ T cells. One study has tried to address this
by generating a T cell-specific knockout of cxcr4 in mice(98). These animals
were born in normal numbers and displayed normal T cell function compared to
wild-type mice, but displayed defective responses to the CXCR4 ligand, SDF-1.
We have previously shown that our CXCR4-ZFN is capable of efficiently
modifying CXCR4 in rhesus macaque cells, providing us with the unique
opportunity of examining the engraftment and trafficking of CXCR4-ZFN edited
CD4+ T cells in a more relevant model system before attempting this approach in
humans(15).
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One potential limitation of this study is the modification of only CD4+ T
cells and not a longer-lived cell population such as hematopoietic stem cells
(HSCs). While previous studies have shown that ccr5 can be efficiently modified
in CD34+ HSCs and this modification results in the production of ccr5 null CD4+
T cells and macrophages that are resistant to infection, CXCR4 signaling plays a
critical role in the homing of HSCs to the bone marrow and as such, loss of
CXCR4 expression on HSCs may result in their unwanted egress into the
peripheral blood(73). However, due to the long half-life of memory CD4+ T cells,
we believe that an approach consisting of modification of ccr5 in HSCs and both
coreceptors in CD4+ T cells will provide patients with a pool of cells resistant to
R5-HIV infection while at the same time preventing the outgrowth of viruses
capable of using CXCR4.
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CHAPTER 4. Translocation capture sequencing reveals the genome-wide
specificity of ZFNs, TALENs and CRISPR/Cas associated nucleases
Contributors to this work include Mary J. Drake (University of Pennsylvania),
Nirav Malani (University of Pennsylvania), Craig B. Wilen (University of
Pennsylvania) and Frederic Bushman (University of Pennsylvania)
I. Introduction
Precision genome engineering allows for the introduction of stable,
heritable genetic modifications into complex organisms in a sequence specific
manner. These modifications are accomplished using one of the three main
classes of designer nucleases—zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs) and clustered regularly interspaced
short palindromic repeat (CRISPR) associated nucleases. Designer nucleases
hold great promise for the treatment of human disease, but a high level of
nuclease specificity is likely required to ensure that their use does not result in
genotoxic effects. To this end, a number of studies have sought to identify sites
of unwanted or off-target cleavage activity for each of these nucleases
(14,15,25,99-103). However, most of these studies either employ approaches
predicated on the assumption that sequence similarity is the primary driver of offtarget activity, or attempt to predict sites of off-target activity based on data
obtained from in silico systems that may not faithfully recapitulate the DNA
binding events that occur in a living cell. While all of these studies have identified
sites of off-target activity with sequence similarity to the target site, a recent study
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took a slightly different approach by co-administering a ZFN and an integration
defective lentiviral vector, and showed that this vector was able to capture sites
of ZFN-induced double strand breaks (DSB)(26). Using this approach the authors
showed that ZFNs are able to cleave sequences with as low as 67% homology to
their on-target sites and importantly, many sites with close to 100% homology to
the ZFN target site showed no signs of nuclease activity (26). These results
suggest that sequence specificity may not be the sole determinant of nucleaseinduced DNA double strand breaks (DSBs). We thus sought to unambiguously
identify all nuclease induced DSBs in cells treated with each of the three main
classes of designer nuclease using a more unbiased approach. We hypothesized
that the simultaneous introduction of two DSBs within a cell by a designer
nuclease—at on and off-target sites—may result in the formation of
translocations between these sites, and we attempted to identify these
translocations using Translocation Capture sequencing (TCseq). TCseq allows
the high throughput identification of chromosomal rearrangements across the
genome (104-107). Using this technique, a recent study showed that
translocations in B-lymphocytes are associated with the rate of repeated sitedirected DNA damage (104-107). In this study, we set out to ask the following
questions: (1) Do double strand breaks generated by a single designer nuclease
at on and off-target loci result in the formation of translocations between these
breaks? (2) Can these translocations be detected using TCseq? (3) Will the
genome-wide characterization of the off-target sites involved in these
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translocations further our understanding of the factors governing the specificity of
these nucleases?
II. Materials and methods
Designer nucleases. In this study, we employed a CCR5-specific Compozr®
Zinc Finger Nuclease (Sigma Aldrich) and a CCR5-specific XTN-TALEN
(Transposagen Biopharmaceuticals). Both the ZFNs and TALENs encoded the
ELD:KKR FokI nuclease domains with obligate heterodimeric FokI activity(84).
CRISPR guide RNAs (gRNA) targeting the ccr5, cxcr4 and vegfa genes were
designed based on the architecture described in (12), and the vegfa sequences
targeted were previously described (103). We obtained a human codonoptimized S. pyogenes Cas9 encoding plasmid from Addgene (Plasmid 41815).
The Cas9 coding sequence was excised from pCDNA3.3 using XbaI and AgeI
and blunt cloned into the BamHI site in the pGEM.64A vector. mRNA Transcripts
derived from the resulting vector (termed pGEM.64A.hCas9) encode a 64nucleotide long polyA tail(108). Sequences targeted by the ZFNs, TALENs and
gRNAs are as outlined in Table 3.

In vitro transcription. To generate GFP, ZFN, TALEN, and Cas9 mRNA’s,
plasmids encoding the respective mRNAs were linearized (XbaI for the ZFN left
and right plasmids, PmeI for the TALEN left and right plasmids, SpeI for the
pGEM.64A.hCas9 and pGEM.GFP.64A plasmids), and transcribed using the
MEGAscript T7 in vitro transcription kit (Life technologies). Reactions were
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performed at 37oC for 16 hours as per manufacturer’s instructions. To ensure
proper capping of transcripts, transcriptions were performed using the 3´-0-Mem7G(5')ppp(5')G RNA Cap Structure Analog (New England Biolabs) at a 4:1 cap
analog to GTP ratio. ZFN and TALEN plasmids were subsequently polyA-tailed
using the A-plus Poly(A) Tailing Polymerase kit (Cellscript). To synthesize a
gRNA mRNA targeting cxcr4, polymerase chain reaction (PCR) was used to
simultaneously amplify the 100bp cxcr4 gRNA and add a T7 promoter to the 5’end of the PCR amplicon (Table 5). This amplicon was subsequently used as a
template for T7 in vitro transcription without a cap analog, as described above.
All mRNA transcripts were purified by lithium chloride precipitation.

Cell culture and designer nuclease delivery. 293T cells were maintained in
DMEM growth media with 10% fetal bovine serum (FBS). For each vegfa
CRISPR transfection, triplicate wells of 4x105 293-T cells were plated in a 12-well
plate. After 24 hours, these cells were transfected with either a GFP encoding
plasmid (pHyg-EGFP, Clontech), or with 5ug each of two plasmids encoding the
desired gRNA (pCRII Blunt TOPO) and the human codon-optimized S. pyogenes
Cas9 (in pCDNA3.3) as previously described (12). Transfections were performed
using Lipofectamine 2000 (Life Technologies) as per manufacturer’s instructions.
Cells were transferred to a 6-well plate 24 hours post-transfection and were
harvested 5 days post-transfection. Each condition was transfected in triplicate in
each of two independent experiments. Genomic DNA from independent
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experiments (~30 million cells per condition) was pooled for sequencing library
preparation.
Jurkat T cells (clone E6-1) were maintained in RPMI growth media
(Invitrogen) supplemented with 10% FBS. ZFNs, TALENs, and CRISPR/Cas
nucleases were delivered to Jurkat T cells by electroporation using a BTXECM830 electroporator (Harvard apparatus BTX, Holliston, MA). Jurkat T cells
were washed three times in OPTI-MEM (Invitrogen) and resuspended at a
concentration of 1x108 cells/mL in OPTI-MEM. For each condition, ~1x107 cells
were mixed with varying amounts of the corresponding nuclease mRNA or DNA
(Table 5) and electroporated in a 0.2cm electroporation cuvette (500V for 700µs).
Cells were immediately transferred to a 6-well plate containing pre-warmed
RPMI+10%FBS at a concentration of 2x106 cells/mL and incubated at 30oC for
24 hours. Following this, cells were maintained at a concentration of 1x106
cells/mL for an additional nine days in a 37oC incubator prior to genomic DNA
extraction for gene modification analysis and sequencing library preparation. For
each condition, genomic DNA from 150-250 million cells obtained from three
independent experiments was pooled for sequencing library preparation.

Quantification of gene modification. Genomic DNA extractions were
performed using the QIAamp DNA Blood Maxi kit (Qiagen) as per the
manufacturers instructions. Mutation frequencies were measured as percent nonhomologous end joining (%NHEJ) using the T7 Endonuclease I assay (T7E1) as
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previously described (87). Primers used to perform the T7E1 assay are as
outlined in Table 4.

Translocation Capture sequencing
Sequencing library preparation. For each sample, three 5µg aliquots of
isolated genomic DNA were fragmented by enzymatic digestion using NEBNext
dsDNA Fragmentase (New England Biolabs) to obtain a size distribution of 1001000bp. Fragmented genomic DNA was purified using the QIAquick PCR
purification kit (Qiagen), and purified DNA was subsequently blunted using the
Quick Blunting™ Kit (New England Biolabs), and adenosine-tailed using the
klenow 3’ ! 5’ exonuclease (New England Biolabs). Each tailed fragment was
ligated to a unique partially double-stranded DNA linker using a Quick ligation kit
(New England Biolabs) to reduce sample contamination as previously
described(109). Linker-ligated samples were pooled and amplified using Phusion
DNA polymerase (New England Biolabs). We performed a first round PCR using
a gene-specific primer located upstream of the nuclease induced double strand
break, and a linker specific primer. A second PCR was performed using 1µl of a
1/50 dilution of the first round PCR as a starting template. The second round
PCR primers were internal to those used in the first round PCR and contained
barcodes to allow for sample multiplexing, and sequences necessary for binding
to an illumina sequencing flow cell as previously described (110). Library
amplification primers are as outlined in Table 6. For Jurkat T cell samples, 8
unique first round PCRs were performed and each of these was used as a
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template for the second round PCR. For each 293T samples, two first round
PCRs were performed and each of these was used as a template for four second
round PCRs. All second round PCR samples were purified using the Agencourt
Ampure XP beads (Beckman Coulter) and equimolar amounts of each sample
were pooled to obtain a final sequencing library.

Data analysis. Paired ends were rejoined and the sequence end originating
within the nuclease-treated gene was aligned to the 30bp genomic sequence
immediately following the sequencing primer, allowing for up to a 2bp mismatch.
This sequence was then trimmed and the remaining sequence was aligned to the
human genome using BLAST with a 90% identity criteria. Two or more reads
were necessary to score a putative translocation event and translocation
frequency was determined by analyzing the number of unique fragment lengths
as previously described(109).

Rearrangement verification. Nested PCR was used for both de novo
identification and for verification of genomic rearrangements. Forward primers
were always designed to anneal to the nuclease target gene upstream of the
nuclease cut-site, while reverse primers were designed to bind the suspected
translocation partner (Table 8). Second round PCR products were cloned into the
pCR Blunt II TOPO vector using the Zero Blunt PCR TOPO kit (Invitrogen).
Following transformation of cloned products individual colonies were analyzed by
Sanger sequencing using the T7-primer included in the kit.
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III. Results
Activity of CCR5-specific ZFNs, TALENs and CRISPRs with an overlapping
target sequence
To enable us compare the specificity of the three main classes of designer
nucleases, we designed and obtained a ZFN, TALEN and CRISPR/Cas nuclease
targeting an overlapping sequence in CCR5 (Figure 8A). Delivery of increasing
amounts of these nucleases to the Jurkat T cell line resulted in a dose-dependent
increase in the level of gene modification at the target loci (Figure 8B).
Additionally, we simultaneously treated these cells with two CRISPRs—one
targeting ccr5 and one targeting cxcr4—to determine whether simultaneous
delivery of two designer nucleases resulted in an exponential increase in the rate
of off-target cleavage, and to serve as a translocation control for future
experiments. Using nested PCR and Sanger sequencing, we were able to
identify reciprocal translocations between the ccr5 and cxcr4 loci involving the
nuclease-induced double stranded breaks at these sites (Figure 9A-B)

A single CRISPR/Cas nuclease generates rearrangements between sites of
on and off-target activity
Several recent studies have identified sites of CRISPR/Cas nuclease offtarget activity(99,101-103). As such, we asked whether we could identify
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rearrangements between these known on- and off-target loci. We employed two
recently described CRISPRs targeting two unique loci in vegfa (termed
VEGFA.T2 and VEGFA.T3). Delivery of either one of these nucleases to 293T
cells results in gene modification at their respective target loci and at several offtarget loci (103) (Figure 10A). Thus we after delivering either nuclease to 293T
cells, we used nested PCR in an attempt to identify rearrangements between
these loci and their previously identified off-target sites. We assayed for 2
rearrangements per CRISPR/Cas nuclease and were able to detect
rearrangements of the expected sizes between all four on and off-target loci
tested (Figure 10B). Using sanger sequencing, we confirmed that these
rearrangements did in fact involve the expected loci (Figure 11A-D).

IV. Discussion
In this ongoing study, we attempted to identify translocations involving
designer nuclease-induced double strand breaks throughout the genome, in the
hope that identification of translocation partners would reveal off-target double
strand breaks caused by these nucleases. We have currently completed our
deep sequencing of the nuclease-treated and control samples and are currently
completing the analysis of this sequence data. However, our interim results prove
that delivery of a single CRISPR/Cas nuclease results in the formation of
detectable rearrangements between sites of on and off-target gene modification.
As such, we expect that the results of our TCseq data analysis will be useful in
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the identification of sites of designer-nuclease induced off-target activity across
the genome.
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CHAPTER 5. Conclusion and Future directions
The focus of this thesis was two-fold—to explore the feasibility of
simultaneously inactivating the two entry factors necessary for infection by the
major forms of HIV using one class of designer nucleases (ZFNs), and to
develop a tool for the genome-wide identification of translocations caused by the
major classes of designer nucleases in an attempt to better understand the
factors influencing the specificity of these nucleases.
In the first project, we showed that simultaneous delivery of two
ZFNs targeting the HIV entry coreceptors ccr5 and cxcr4 results in stable
inactivation of these genes in primary human CD4 T cells—the primary target of
HIV infection. We then went on to show that these gene-modified cells are
protected from infection by viruses that use either CCR5 or CXCR4 to infect
cells, and have a survival advantage in the presence of these viruses. Using a
humanized mouse model, we showed that animals harboring cells that lacked
both coreceptors were better able to maintain their CD4 counts following infection
with viruses that use both coreceptors. In fact, following virus challenge, animals
with the gene modified cells had greater than 100-fold higher CD4 T cell counts
on average than animals with wild-type cells. Additionally, analysis of the genemodified cells following in vivo challenge revealed enrichment for gene-modified
cells only in the presence of infection—supporting the hypothesis that knockout
of both of these entry factors confers a survival advantage on primary CD4 T
cells lacking these genes in the face of HIV infection. These results have
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important implications for the field of HIV cure research. Specifically, our study
has attempted to both phenocopy the remarkable cure achieved following the
allogeneic transfer of stem cells from a ccr5∆32 homozygous donor to a wild-type
HIV-infected recipient(59,111) and extend upon those results by generating cells
resistant to HIV-1 viruses that use either coreceptor (CCR5 or CXCR4) to infect
cells. In this study, we utilized a humanized mouse model, which is a useful one
for studying HIV infection in vivo. However, we will conduct future studies in a
rhesus macaque infection model that more accurately recapitulates human HIV
infection. The macaque model will allow for a more thorough investigation of the
effects of our approach on HIV infection, including its effects on viral load, the
DNA viral reservoir, and its ability to reconstitute the immune system—all in the
setting of a prolonged antiretroviral therapy treatment interruption. In this model,
we will also be better able to test the effect of loss of these coreceptors on T cell
functionality by measuring the engraftment, trafficking, and longevity of these
cells over an extended period of time in vivo. This model will also allow us to
initially infect the animals, and subsequently perform an autologous transplant of
gene-modified cells, to more closely mimic how this therapy will be administered
in humans. Finally, this model will allow us test our long-term approach of
modification of ccr5 in both CD34+ hematopoietic stem cells and CD4 T cells,
and modification of cxcr4 in CD4 T cells alone.
Although inactivation of the viral coreceptors appears to be a logical
approach to control HIV infection, what is less obvious is the amount of
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coreceptor ablation required to observe a therapeutic effect. Data from ccr5∆32
heterozygotes suggests that even partial coreceptor ablation may be of clinical
benefit as these individuals display delayed disease progression following HIV
infection(112). As such, the current ZFN technology may provide a therapeutic
benefit despite not completely eliminating coreceptor expression. In support of
this, in a recent phase I study of HIV-infected patients who received autologous
R5-ZFN modified CD4+ T cells, a number of these patients exhibited viral load
decreases compared with pretreatment levels following a 12-week interruption of
ART (Carl H. June, University of Pennsylvania, written communication, May 23,
2013). Of note, the viral load in one of these patients reached undetectable levels
prior to the reinstatement of ART and further analysis revealed this patient to be
a ccr5∆32 heterozygote. Despite the modest number of patients enrolled in this
study, it is tempting to speculate that even the relatively low levels of coreceptor
ablation achieved by ZFN modification may be of therapeutic benefit, and that
this benefit will only increase as the expression of either coreceptor is further
reduced.
A potential limitation associated with any approach that targets CCR5
alone is the presence of virus strains that utilize CXCR4. Clinical failure
associated with the use of the CCR5 antagonist maraviroc is either the result of
an outgrowth of pre-existing virus strains that use CXCR4 and continue to
replicate despite CCR5 blockade(65), or mutations that arise in the viral
glycoprotein allowing it to use the drug-bound form of CCR5(113), a resistance
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pathway not available to the virus when ccr5 is disrupted by ZFN technology. The
fact that X4 HIV-1 strains can be present at low levels in chronically infected
individuals provides a powerful rationale for employing a strategy that targets
both ccr5 and cxcr4(114). While R5 ZFNs have been used to ablate ccr5 in
hematopoietic stem cells (HSCs) to provide a self-renewing population of CCR5
negative cells, CXCR4 signaling plays a critical role in the bone marrow retention
of HSCs(115,116). As a result, loss of CXCR4 expression on HSCs may result in
their unwanted egress into the peripheral blood. Although less is known about
the effects of the specific loss of CXCR4 expression on CD4 T cells, a recent
study of T cell-specific cxcr4 knockout mice showed that these animals are born
in normal numbers and display humoral and cellular responses indistinguishable
from those of wild-type mice(98), suggesting that loss of CXCR4 expression on
CD4 T cells may be immunologically tolerated.
Our work and that of others provides compelling evidence for the ability of
ZFN-mediated coreceptor ablation to protect CD4+ T cells and provide virologic
control of HIV infections. However, a number of questions remain regarding the
clinical efficacy of this approach and the ease with which it can be implemented.
While the original transplant using ccr5∆32 cells resulted in a cure, other factors
may have contributed to this outcome including reductions in reservoir size by
the conditioning chemotherapy and graft-versus-host disease experienced by the
patient. Allogeneic HSCT has long been known to exert an anti-tumor or graft vs
tumor effect (117). While there is conflicting evidence on the effect of allogeneic
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HSCT on HIV infection (reviewed in (118,119)), the idea that complete donor
chimerism, if achieved following an allogeneic HSCT, would effectively cure an
established HIV infection is an interesting one. For this to occur, the donor cells
would likely need to be protected from infection during the transition to complete
donor chimerism, and in the case of the ccr5∆32 transplant that resulted in a
cure, that was achieved by using cells resistant to HIV infection. Another instance
where protection of newly infused donor cells may have provided a clinical
benefit in HIV infection is in the recent case of the ‘Boston patients.’ In this small
study, three HIV-positive patients in Boston received allogeneic HSCT following
reduced-intensity chemotherapy to treat lymphoma. The patients were kept on
ART for up to 4 years following transplant and while only two patients survived,
they were both shown to have a significantly lower viral reservoir as measured by
viral outgrowth following maximum in vitro T cell activation (66). Moreover, these
patients have recently undergone ART interruption and while results are only
available for a few months post-ART interruption, there is no evidence of viral
rebound as measured by viral RNA or DNA in the peripheral blood and rectal
tissues of either patient [91]. This report is remarkable for two reasons—the
cells used in the HSCT did not lack CCR5, and the procedure was performed
with a reduced intensity chemotherapy regimen. This approach—if successful—
may sidestep some of the issues of HSCT toxicity related to chemotherapy, and
the relatively low frequency of ccr5∆32 homozygous donors that has plagued
attempts to repeat the success of the first cure. However, as the Boston patients
have only been off ART for a short period of time, and prior HSCTs performed in
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HIV-infected individuals who were subsequently placed on ART have not
resulted in a cure (118,119), it remains to be seen whether the transplants have
actually cured their infection or simply delayed the return of the virus. Of note, the
patient who received a transplant using ccr5∆32 cells and both Boston patients
who survived allogeneic HSCT with ccr5 wild-type cells were all ccr5∆32
heterozygotes at baseline. At this time, however, it is not known whether their
baseline ccr5∆32 heterozygosity could have provided any added benefit in the
form of a smaller viral reservoir, or even a less severe course of their GVHD.
[92,93]
Although ART does not fully restore health, its introduction has resulted in
a near-normalization of the life expectancy of HIV-infected individuals, and as
such, future studies must determine whether ZFN treated cells can sufficiently
control viral replication, restore normal immune function, and decrease the viral
reservoir, as these features of HIV infection must be impacted if we hope to
achieve a cure(48,120)—functional or otherwise—in HIV infected individuals.
In the second part of my thesis, I set out to ask the following three
questions: (1) Do double strand breaks generated by a single designer nuclease
at on and off-target loci result in the formation of translocations between these
breaks? (2) Can these translocations be detected using Translocation Capture
sequencing (TCseq)? (3) Will the characterization of the off-target sites involved
in these translocations further our understanding of the factors governing the
specificity of these nucleases?
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While this study is still ongoing, we were able to address our first question.
Using nested PCR, we were able to identify rearrangements involving double
strand breaks generated by a CRISPR/Cas nuclease at its on- and off-target loci.
We hope that our TCseq analysis will provide much deeper insight into the
genome-wide distribution of designer nuclease induced rearrangements.
However, the identification of these rearrangements highlights two extremely
important issues facing the field of precision genome engineering—the paucity of
functional readouts of off-target activity, and the need to define an ‘acceptable’
level of off-target activity, if indeed such a thing exists.
While several studies have identified sites of designer nuclease off-target
activity, few have gone on to address the consequences of these off-target
effects. This is in part due to the fact that a large proportion of these off-target
modifications occur either in non-coding regions, in genes of unknown function,
or occur at a relatively low frequency compared to the off-target site. And while a
low level of modification in a non-coding sequence may be of little consequence,
our work has shown that a single designer nuclease can result in translocations
between protein-coding genes. The identification of these translocations provides
us the unique opportunity to begin to probe the biological products of off-target
gene modification. Specifically, we can begin to assess the oncogenic potential
of designer nucleases by analyzing the rearrangements they produce and any
fusion proteins that may result. Additionally, TCseq provides a rapid means of
assessing the genome-wide specificity of any designer nuclease, and as such,
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can be used to quickly determine whether improvements in nuclease architecture
result in a decrease in genome-wide off-target activity.
The second equally important issue highlighted by this study is the need to
define an acceptable safety profile for a given designer nuclease. Early studies
attempted to do this by using the in vitro toxicity of a nuclease as a readout for its
safety. However, this approach likely overlooks a myriad of potentially genotoxic
mutations whose phenotypes may not result in death, but may prove quite
harmful in vivo. The benefits of our approach are two-fold—it may provide the
most comprehensive analysis of genome-wide off-target profiles for any designer
nucleases tested—and these profiles are linked to translocations that can be
directly tested for biological activity. This functional readout may allow for the
detection of clinically actionable rearrangements that occur following the delivery
of a single designer nuclease.
The field of genome engineering has huge potential for changing the way
we grow crops, breed animals, and treat humans, and I hope that this thesis has
yielded useful contributions to this burgeoning and exciting field.
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Figures and Tables
Table 1. Gene therapy clinical trials targeting the major steps in HIV entry

Step%in%Entry%Targeted%
CD4%binding%
CD4%binding%
CD4%binding%
CCR5%binding%

%%gene%marked%cells%at%
study%conclusion%
CD4$zeta)chimeric)T)cell) Autologous)CD4+)and)CD8+) 0.1%)of)PBMCs)at)1)
receptor))
T)cells)
year)
CD4$zeta)chimeric)T)cell) Syngeneic)CD4+)and)CD8+)T) 0.1$1%)of)CD4+)and)
receptor))
cells)
CD8+)T)cells)at)1)year)
CD4$zeta)chimeric)T)cell) Autologous)CD4+)and)CD8+) 0.1$10%)of)PBMCs)at)
receptor))
T)cells)
24)weeks)
shRNA)targeMng)tat/rev,)TAR)
Autologous)CD34+)
0.01%)of)whole)blood)
decoy,)CCR5)ribozyme)
HematopoieMc)stem)cells)
at)18)months)
Transgene/Payload%

Target%cell%

CCR5%binding%

CCR5)speciﬁc)Zinc)Finger)
Nuclease)

Autologous)CD4+)T)cells)

Completed)

CCR5%binding%

CCR5)speciﬁc)Zinc)Finger)
Nuclease)(dose)escalaMon))

Autologous)CD4+)T)cells)

Ongoing)

CCR5%binding%

CCR5)speciﬁc)Zinc)Finger)
Nuclease)(dose)escalaMon,)
with)cyclophosphamide))

Autologous)CD4+)T)cells)

Ongoing)

CCR5%binding%

CCR5)speciﬁc)Zinc)Finger)
Nuclease)

Autologous)hematopoieMc)
stem)cells)

Ongoing)

HIV%fusion%

HIV)fusion)inhibitory)pepMde)
maC46)

Autologous)CD4+)T)cells)

Less)than)0.01%)of)
leukocytes)aaed)day)7)
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Reference%
63)
64)
65)
77)

hWp://clinicaltrials
ct2/show/
NCT00842634
hWp://clinicaltrials
ct2/show/
NCT01044654
hWp://clinicaltrials
ct2/show/
NCT01543152
California)InsMtut
RegeneraMve)Med
grant)#)DR1$014
86)

Table 2. Indel frequency at predicted off-target sites following simultaneous treatment of
primary CD4+ T cells with the R5- and X4-ZFNs
Mock*treated*samples
Arrangement

Start*Site

R5ZFN&L_N5_R5ZFN&R

46414544

Chromosome Mismatches

Gene

Total*Reads

%indels*(M)

Total*Reads

%indels*(Z)

(Z;M)Indel%

(Z;M)/M

Conclusion

chr33

0

CCR5

6033

0.10

5987

28.04

27.94

280.98

on3target

136872909 CCACCCACAAGTCATTGGGGTAGAAGCGGTCA chr3

0

CXCR4

7836

0.14

6937

20.87

20.73

147.70

on3target

X4ZFN&L_N5_R5ZFN&R3
R5ZFN&R_N5_X4ZFN&L3
X4ZFN&L_N6_R5ZFN&R3
X4ZFN&L_N5_R5ZFN&R3
X4ZFN&L_N6_R5ZFN&R3

98297881
109228230
27016543
21632080
1850892

AGtCCGCTTCTAaAGAGTAAACTGCAtAAGT
AaTTTTACGGTTaACAATGgAGAAGCGGTAC
AGACCGCTTCTAtATCCATAAAaTGGAgAAGA
GTGCCGgTTCTACCAGCTgAACaGGAAAAGC
ATGCCaCTTCTACCGAGACcAACTGGAAAtGA

chr13
chr63
chr33
chr143
chrY3

3
3
3
3
3

DPYD
ARMC2

12597
13042
19337
14143
12096

0.16
0.09
0.01
0.11
0.05

18538
14217
20643
14975
16228

0.18
0.07
0.02
0.15
0.01

0.02
&0.02
0.01
0.04
&0.04

0.12
&0.24
1.34
0.39
&0.75

no3activity
no3activity
no3activity
no3activity
no3activity

X4ZFN&R_N6_R5ZFN&L3
X4ZFN&R_N5_R5ZFN&L3
X4ZFN&R_N5_R5ZFN&L3
X4ZFN&R_N5_R5ZFN&L3
X4ZFN&R_N6_R5ZFN&L3
X4ZFN&R_N5_R5ZFN&L3
R5ZFN&L_N6_X4ZFN&R3
R5ZFN&L_N6_X4ZFN&R3
X4ZFN&R_N5_R5ZFN&L3
R5ZFN&L_N6_X4ZFN&R3
X4ZFN&R_N5_R5ZFN&L3
R5ZFN&L_N6_X4ZFN&R3
R5ZFN&L_N6_X4ZFN&R3

75770618
12941646
71635397
110885753
14425533
7279610
3238977
43748539
49133212
43421403
8681224
128765042
71871779

ACACCtCCAGGaCTACATGGcTGAGGATGAgG
TCACCCCCAGtTCACCCTGAgGAGtAgGACG
GCACCtCCAAGTCCTCACGAgGAGGcTGAgA
ACACCCtCgGGTCCTGCAGATGAGCcTGAgT
GCACCCCCtGGgtCTCCGGGATGAGGAgGACC
CCACCCACtAtTCCAGCTacTGAGGATGACT
CcTCATCCTCAgCAGGCCTGgCTgGGGGGTGG
CaTCATCCTCATCTTCAGCcACCTGTGGGcGG
TCACCCgCAAGTCCCAGAGtTGAGGcTGACA
TcTCATCCTCAgCACCGTTGACCTtTGGGaGC
GaACCCACAGGTCACCGAGAaGAGCATcACC
TcTCATtCTCATCCCCTGTGACTTGGcGGTcC
GGTCATCCTCAgCAGAGTGGACTaaGGGGTcC

chr63
chr173
chr103
chr133
chr193
chr103
chr113
chr13
chrX3
chr123
chr83
chr113
chr173

4
4
4
4
4
4
4
3
3
4
3
4
4

9270
10491

0.01
0.35

8412
12447

0.05
0.27

12581

0.14

18794

0.87

2948
8665
6886
4114
7212
4315
14699
3888
10649
14648

0.68
0.23
0.28
4.64
0.60
0.28
0.03
0.08
0.08
1.65

2541
6073
10020
3224
4421
5128
15132
4260
20127
11586

0.12
0.33
0.15
4.47
0.54
0.33
0.02
0.02
0.04
0.47

0.04
&0.08
0.72
&0.56
0.10
&0.13
&0.18
&0.05
0.05
&0.01
&0.05
&0.03
&1.18

3.41
&0.23
5.06
&0.83
0.43
&0.46
&0.04
&0.09
0.19
&0.42
&0.70
&0.40
&0.72

no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity

R5ZFN&R_N6_X4ZFN&R3
R5ZFN&R_N6_X4ZFN&R3
R5ZFN&R_N5_X4ZFN&R3
R5ZFN&R_N6_X4ZFN&R3
R5ZFN&R_N5_X4ZFN&R3
X4ZFN&R_N6_R5ZFN&R3
R5ZFN&R_N6_X4ZFN&R3

92737093
36865579
2796248
99258148
102430357
25532770
175289032

AaTTTTGCAaTTaAAATGGGACTTGGGGGTGA
TCTTTTAtGGTTTCGGTTGGAaTTGTGGGTGG
TCTTTTCtAGTTTCCTCTGACCTGTGGGTtG
CCTTTTGCAGTTTCTGCTGGACaTcaGGGTGA
TCTTTTTCGGTTTTGTGTGAaTcGTGGGTGT
CCACCCCCAAGTCCCTTTTAcACTaCAAAAaT
TCaTTTCaGGTcTTCTATGGACTTGTGGGTGG

chr93
chr133
chr63
chr73
chr63
chr33
chr33

3
2
2
3
2
3
3

4238
10186
9217
7999
12758
11035
13488

0.17
0.01
0.03
0.24
0.29
0.42
0.08

3712
17088
7702
8135
12006
9146
16734

0.27
0.05
0.04
0.25
0.42
0.31
0.14

0.10
0.04
0.01
0.01
0.13
&0.11
0.06

0.63
4.36
0.20
0.04
0.46
&0.27
0.76

no3activity
no3activity within3assay3noise
no3activity
no3activity
no3activity mostly3large3deletions,3likely3PCR3artifact
no3activity
no3activity

X4ZFN&L_N6_R5ZFN&L3
X4ZFN&L_N6_R5ZFN&L3
R5ZFN&L_N6_X4ZFN&L3
R5ZFN&L_N6_X4ZFN&L3
R5ZFN&L_N6_X4ZFN&L3
R5ZFN&L_N6_X4ZFN&L3
X4ZFN&L_N6_R5ZFN&L3
X4ZFN&L_N5_R5ZFN&L3
R5ZFN&L_N5_X4ZFN&L3
X4ZFN&L_N5_R5ZFN&L3
R5ZFN&L_N5_X4ZFN&L3
X4ZFN&L_N6_R5ZFN&L3
X4ZFN&L_N6_R5ZFN&L3
X4ZFN&L_N5_R5ZFN&L3
X4ZFN&L_N5_R5ZFN&L3

103817758
141380550
85231512
68402483
105663998
129253775
763557
42517731
180652373
90025463
68589345
30834644
9859397
125124276
242334646

ATGCCGCTTCTgCCTGCAAGATGAGaAaGACA
AGACaGCTTCTACCATGTGGATGAGGAcaACA
TcTCtTCCTCATCCACTTGcTAGAAGCaGTCC
AGTCATCCgCATCCACCAAGTAGAAGgGGaAA
CcTCcTCCTCcTCCTCCTAGTAGAAGCtGCAC
GGTCAgCCTCATCCCATGCGTtGAAGaGGCCT
ATcCCGCaTCTACGCCAGTGAgGAGGATGACT
AGGCCGCTTCTACTTACGGcTGAaGAgGAaG
TGTCcTCCTCtTCAACTCGTtGAAaCGGTCT
GCACCGCTTtTACAAGGAGAaGAGCAaGAgC
GGTCATGCaCcTCACTCAGTAGAAGgGGCCA
AGACCaCTTgaACTAATAGGAgGAGGATGACG
ACGCtGCTaCTgCCTGGGGGcTGAGGATGACA
TGGCaGCTTCaACCTGCAGATGAGCAaGAaC
GCtCCtCTTCTACTTAGAGcaGAGGATGACT

chr83
chr73
chr13
chr123
chr73
chr103
chr193
chr83
chr23
chr163
chr163
chr23
chr33
chr33
chr23

3
3
4
3
4
3
3
4
4
4
3
4
4
4
4

5667
12880
9306
6868
3485
13892
9110
3877
5346
9942
13813
8239
7200
13684
6502

0.02
0.17
0.03
0.16
16.24
0.13
3.30
0.15
0.06
0.03
0.04
1.27
0.18
0.07
0.29

6578
9524
8144
8244
4769
14547
5441
6052
8293
10837
12597
8538
5330
20006
9157

0.05
0.06
0.06
0.29
18.87
0.34
4.30
0.08
0.05
0.06
0.02
0.62
0.26
0.02
0.32

0.03
&0.11
0.03
0.13
2.63
0.21
1.00
&0.07
&0.01
0.03
&0.01
&0.65
0.08
&0.05
0.02

1.58
&0.63
0.90
0.82
0.16
1.60
0.30
&0.47
&0.14
1.14
&0.34
&0.51
0.45
&0.70
0.08

no3activity
no3activity
no3activity
no3activity
no3activity likely3PCR3artifact3due3to3presence3of3repeated3shor
no3activity
no3activity mostly3large3deletions,3likely3PCR3artifact
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity
no3activity

X4ZFN&L_N6_X4ZFN&R

Site

R5/X4;ZFN*treated*samples*
(MOI_500/500)

GTCATCCTCATCCTGATAAACTGCAAAAG

COL13A1
COL4A1
SFMBT2
C1orf210
PPP1R3F
MFHAS1
KCNJ5

C13orf38
CYP3A5
GRIK2
RARB
NAALADL2

KIAA1147

FLJ23834
C19orf21
ZNF385B
DEF8
ZFP90
LCLAT1
TTLL3
FARP2

N5/N63refers3to3the3length3of3the3spacer3between3the323members3of3the3ZFN3pair3ie3either353or36bp

(Z&M)/M3needs3to3be3>=23to3be3considereded3as3specific
Lowercase3letters3in3sequence3indicate3base3mismatches
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Comments

within3assay3noise

mostly3large3(40&80bp)3deletions,3likely3PCR3artifact

mostly3large3deletions,3likely3PCR3artifact

mostly3large3deletions,3likely3PCR3artifact

Table 3. Sequences targeted by ZFNs TALENs and CRISPRs used in this study
Plasmid

Target gene

Target sequence

PZFN1

CCR5

ACCTGCAGCTCTCAT

PZFN2

CCR5

ATACAGTCAGTA

TAL-left

CCR5

TTCATTACACCTGCAGCT

TAL-right

CCR5

AGTATCAATTCTGGAAGA

CCR5.gRNA

CCR5

ATACAGTCAGTATCAATTCTGG

CXCR4.gRNA

CXCR4

TTCTACCCCAATGACTTGTGGG

VEGFA.T2.gRNA

VEGFA

GACCCCCTCCACCCCGCCTCCGG

VEGFA.T3.gRNA

VEGFA

GGTGAGTGAGTGTGTGCGTGTGG	
  

Protospacer–adjacent motif (PAM) sequences are noted in bold)

Table 4. T7E1 and transcription template preparation primers
Gene
target

Forward
primer
name

CCR5

R5.T7E1.F* TTAAAAGCCAGGACGGTCAC

Reverse
primer
name

Forward primer sequence

Reverse primer
sequence

Use

TGTAGGGAGCCCAGAA
R5.T7E1.R* GAGA
T7E1

CXCR4 X4.T7E1.F* CAACCTCTACAGCAGTGTCCTCATC

GGAGTGTGACAGCTTG
X4.T7E1.R* GAGATG
T7E1

VEGFA. VT2.T7E1.F
T2
*
AGAGAAGTCGAGGAAGAGAGAG

VT2.T7E1.R CAGCAGAAAGTTCATGG
*
TTTCG
T7E1

VEGFA. VT3.T7E1.F
T3
*
TCCAGATGGCACATTGTCAG

VT3.T7E1.R AGGGAGCAGGAAAGTG
*
AGGT
T7E1

T7
promo
ter
CXCR4 X4.T7.gRNA GAAATTAATACGACTCACTATAGTTCTACCCCA X4.T7.gRNA GCACCGACTCGGTGCC additio
gRNA .F**
ATGACTTGTG
.R**
ACTTT
n

*CXCR4, VEGFA.T2 and T3 primers were previously published; CCR5 primers were obtained
from Sigma Aldrich Compozr ZFN kit
**Underlined sequence is T7 promoter, Bold sequence is CXCR4 gRNA sequence
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Table 5. Nuclease doses and delivery methods used in study
Cell
Type

Gene
target

Nuclease type

Nuclease delivery
method

Nuclease
dose

Nuclease
amount (μg)

Jurkat

None
(GFP)

mRNA

BTX
electroporation

Single
dose

10μg GFP

Jurkat

CCR5

ZFN mRNA

BTX
electroporation

Low

2μ-left/2μgright

Jurkat

CCR5

ZFN mRNA

BTX
electroporation

Medium

10μg-left/10μgright

Jurkat

CCR5

ZFN mRNA

BTX
electroporation

High

20μg-left/20μgright

Jurkat

CCR5

TALEN mRNA

BTX
electroporation

Low

2μ-left/2μgright

Jurkat

CCR5

TALEN mRNA

BTX
electroporation

Medium

10μg-left/10μgright

Jurkat

CCR5

TALEN mRNA

BTX
electroporation

High

20μg-left/20μgright

Jurkat

CCR5

Cas9-mRNA/CCR5
gRNA-DNA

BTX
electroporation

Low

10μg Cas9/2μg
gRNA

Jurkat

CCR5

Cas9-mRNA/CCR5
gRNA-DNA

BTX
electroporation

High

10μg Cas9/4μg
gRNA

Jurkat

CCR5 &
CXCR4

Cas9-mRNA/CCR5
gRNA-DNA/CXCR4
gRNA-mRNA

BTX
electroporation

Single
dose

20μg Cas9/2μg
CCR5
gRNA/2μg
CXCR4 gRNA

293T

None
(GFP)

DNA

Lipofectamine
2000

Single
dose

10μg GFP

293T

VEGFA.T2

Cas9-DNA/gRNADNA

Lipofectamine
2000

Single
dose

5μg Cas9/5μg
gRNA

293T

VEGFA.T3

Cas9-DNA/gRNADNA

Lipofectamine
2000

Single
dose

5μg Cas9/5μg
gRNA
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Table 6. Gene-specific amplification primers used in sequencing library preparation
Primer name

Primer sequence

Notes

CCR5 primer F1

GTGGCTGTGTTTGCGTCTCT

Round 1
PCR

CAAGCAGAAGACGGCATACGAGATATCACGAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.1 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATCGATGTAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.2 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATTTAGGCAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.3 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATTGACCAAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.4 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATACAGTGAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.5 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATGCCAATAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.6 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATCAGATCAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.7 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATACTTGAAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.8 TTACCA
PCR
CAAGCAGAAGACGGCATACGAGATGATCAGAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
CCR5 primer F2.9 TTACCA
PCR
CCR5 primer
F2.10

CAAGCAGAAGACGGCATACGAGATTAGCTTAGTCAGTCAGCCTCCCAGGAATCATCT Round 2
TTACCA
PCR

VT2.T7E1.F

AGAGAAGTCGAGGAAGAGAGAG

Round 1
PCR

VEGFA.T2.F2.illu CAAGCAGAAGACGGCATACGAGATTCCCTTGTCTCCAGTCAGTCAGCCCCCCAGCTA Round 2
mina.1
CCACCTCCT
PCR
VEGFA.T2.F2.illu CAAGCAGAAGACGGCATACGAGATACGAGACTGATTAGTCAGTCAGCCCCCCAGCTA Round 2
mina.2
CCACCTCCT
PCR

VT3.T7E1.F

Round 1
PCR

TCCAGATGGCACATTGTCAG

VEGFA.T3.F2.illu CAAGCAGAAGACGGCATACGAGATACGAGACTGATTAGTCAGTCAGCCGCAGACGG Round 2
mina.1
CAGTCACTAGG
PCR
VEGFA.T3.F2.illu CAAGCAGAAGACGGCATACGAGATGCTGTACGGATTAGTCAGTCAGCCGCAGACGG Round 2
mina.2
CAGTCACTAGG
PCR
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Table 7. Linker amplification primers used in sequencing library preparation
Primer
name

Primer sequence

Notes

L1 PCR1 CGCACCCAGTATTCAACAGGTA

Round 1 PCR

L2 PCR1 GTTTGAGATGCCTACGCCATCC

Round 1 PCR

L3 PCR1 TGGTCGGCGAACAATAGTGGTT

Round 1 PCR

L4 PCR1 TTCAGGAGGTCACTTCGCACAT

Round 1 PCR

L6 PCR1 TAGACCGCTCAGAGGTCATACT

Round 1 PCR

L7 PCR1 CATCGTCGACACACGTGATGAC

Round 1 PCR

L8 PCR1 TATGCGGGACAGGTAATACGCG

Round 1 PCR

L9 PCR1 GGAATCTATGTAGCAGGTCGCT

Round 1 PCR

L10
PCR1

CGCTTTGAGCTATGAACCCTAT

Round 1 PCR

L11
PCR1

AATGCGACACGCATCCTGATTT

Round 1 PCR

L12
PCR1

ATTGAAGGATCCGCCTCTCTAT

Round 1 PCR

L13
PCR1

GAGTCGAATGGTGTATACCTCA

Round 1 PCR

L14
PCR1

TTATTGCGGTAGTGAGGAAGGT

Round 1 PCR

L15
PCR1

GAATCCAGTAAGATCCGTGTGT

Round 1 PCR

L1 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGTAGT
primer
TCCTCGGATCATGTCA
Round 2 PCR
L2 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTCCGG
primer
TCTCTCATTAACTGGA
Round 2 PCR
L3 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGTTGA
primer
ACGGACAGATTAGTGC
Round 2 PCR
L4 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTCATTG
primer
CTTCTTCCCACTAGAG
Round 2 PCR
L6 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTACTTG
primer
CACTTCTGACCTAGCT
Round 2 PCR
L7 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGACGA
primer
GTCAGTCCTACTAAAG
Round 2 PCR
L8 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTACGCG
primer
AGCCAGACTCCATATT
Round 2 PCR
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L9 PCR2 AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTCGCT
primer
AGAGTACGGCCTTGAA
Round 2 PCR
L10
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTATTG
AGAGAGGGAAAGAGGC
Round 2 PCR

L11
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTTTCG
GGCCTGATTTACTTCG
Round 2 PCR

L12
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTATTG
TTTGAAGGGACGCACG
Round 2 PCR

L13
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTCTCAC
CCGTTCTGGAGACTT
Round 2 PCR

L14
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTAGGTC
GAGTCTTGGGTAGGT
Round 2 PCR

L15
PCR2
primer

AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTGTGT
CTGCTTCCGCATCAGT
Round 2 PCR
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Table 8. PCR Primers used for nested PCR to detect rearrangements.
Primer name

Primer sequence

VEGFA.T2.F PCR1

AGAGAAGTCGAGGAAGAGAGAG

VEGFA.T3.F PCR1

TCCAGATGGCACATTGTCAG

VEGFA.T2.F PCR2

ACAGGGGCAAAGTGAGTGAC

VEGFA.T3.F PCR2

GAAGCAACTCCAGTCCCAAA

VEGFA.OT2-1.R
PCR1

TGCTCTGGATAAAGCACAAA

VEGFA.OT2-1.R
PCR2

ACTGATCGATGATGGCCTATGGGT

VEGFA.OT2-2.R
PCR1

TCCTGTCACAATTCCCTGAA

VEGFA.OT2-2.R
PCR2

GCAGCCTATTGTCTCCTGGT

VEGFA.OT3-2.R
PCR1

GGTTTCTTCCGGGATTTGTA

VEGFA.OT3-2.R
PCR2

TACCCGGGCCGTCTGTTAGA

VEGFA.OT3-18.R
PCR1

CACTGAAGCAGAGAGTAGAATGG

VEGFA.OT3-18.R
PCR2

GTTGCCTGGGGATGGGGTAT
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Figure 1. Designer nuclease mechanism of action. (A) Architecture of zinc finger nucleases
(ZFNs) and Transcription activator-like effector nucleases (TALENs). In a ZFN, each ZFP binds
3-4 base pairs of DNA, while each repeat divariable residue (RVD; colored squares, top right
panel) binds a single nucleotide. (B) Schematic depicts binding of a Cas9/crRNA/tracrRNA
complex to a target sequence (protospacer) (C) Depiction of the events following the introduction
of a double strand break which result in genomic alterations—gene disruption following incorrect
repair by non-homologous end-joining, gene correction or gene substitution following repair by
homologous recombination. Image adapted from Current Opinion in Plant Biology, Vol 16/ Issue
2, Hao Chen,Yongjun Lin, Promise and issues of genetically modified crops, 255-260 Copyright
(2013), with permission from Elsevier.
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Figure 2. The HIV Entry Process involves the CD4 receptor, and CCR5 or CXCR4
coreceptors. The figure below outlines a model for HIV Entry. The entry process begins with
binding of gp120 (red) to its primary cellular receptor CD4 (green). CD4 binding results in
conformational changes that allow binding of gp120 to the coreceptor—either CCR5 or CXCR4.
Coreceptor binding results in triggering of the fusion machinery and formation of the six-helix
bundle required to drive fusion of the viral and host cell membranes. Also pictured are the two
main steps that have been successfully targeted (coreceptor binding and viral fusion – approved
therapeutics appear in parentheses) along with the primary target of most genetic therapies
aimed at preventing HIV entry (in red). There are no approved therapies in this latter group.
Adapted from Antiviral Research Vol 85, Tilton J.C. and Doms R.W, “Entry inhibitors in the
treatment of HIV-1 infection,” 91-100, Copyright 2009, with permission from Elsevier.
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Figure 3 – Simultaneous ZFN modification of ccr5 and cxcr4 protects SupT1-R5 T cells from
infection with viruses that use either CCR5 or CXCR4. (A) Surface expression of CCR5 (R5) and CXCR4
(X4) on SupT1-R5 cells following delivery of increasing multiplicity of infections (MOI) of the Ad R5- and X4ZFNs. Percent of cells lacking both coreceptors is labeled in red. (B) Proportion of cells lacking both surface
R5 and X4 (double negative cells) following simultaneous treatment with the R5 (MOI 600) and X4 (MOI
600) ZFNs as measured by FACS. (C) Dual ZFN treated cells were challenged with a mix of R5- and X4using HIV and surface expression of R5 and X4 was measured over time in infected and uninfected R5/X4ZFN treated cells. (D) The proportion of double negative cells following R5/X4-ZFN treatment and
subsequent HIV infection was measured by FACS five and 25 days post-infection. (E) Cell viability after
infection of mock (no ZFN) or R5/X4-ZFN treated supT1-R5 cells with a mix of R5- and X4-HIV. Viability was
measured by FACS following treatment with a viability dye). (F) Dual-ZFN treated supT1-R5 cells previously
challenged with HIV and no longer expressing either coreceptor (black bars) as shown in panel C, were rechallenged with either R5-HIV, X4-HIV or VSV-G-HIV pseudoviruses expressing GFP. HIV pseudovirus rechallenge of previously HIV-selected double negative cells resulted in 170-fold and 92-fold decreases in
infection by R5 and X4-HIV respectively, whereas VSV-G pseudovirus infection was decreased only ~1.7fold. All graphs represent the mean (± standard error of the mean (SEM)) of four independent ZFN
treatments and four independent infection experiments; P-values calculated using student’s t-test.
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Figure 4 –ZFNs simultaneously disrupt ccr5 and cxcr4 in primary human CD4+ T cells. (A) Dual ZFN
treatment does not result in a significant growth defect as determined by live primary CD4+ T cell count
following simultaneous delivery of increasing amounts of the R5 and X4-ZFNs. Data is from one of three
independent experiments. (B) ccr5 and cxcr4 gene modification increases in a dose-dependent manner
following R5/X4-ZFN treatment, as measured by the Cel1 assay 7-10 days post-ZFN treatment. Data is from
one of three independent experiments. (C) Primary CD4+ T cells were sorted by CXCR4 expression into
CXCR4 high and CXCR4 low populations (left) following simultaneous R5/X4-ZFN treatment. Successful
sorting was confirmed by repeat FACS (right panel). Arrows indicate gating strategy. (D) ccr5 and cxcr4
gene disruption was measured by cel1 following R5/X4-ZFN treatment and subsequent sorting by FACS into
CXCR4-high and low populations. ccr5 disruption is similar in the X4 high and X4 low populations
suggesting ccr5 and cxcr4 disruption are not occurring in mutually exclusive cells. Data is from one of three
independent experiments. (E) CD4+ T cells treated with equal MOIs of the AdGFP or the R5- and X4-ZFNs
were stained with the memory markers CCR7 and CD45RO. (Tcm; CD45RO+CCR7-) and effector memory
T cells (Tem; CD45RO+CCR7-). (F) ccr5 and cxcr4 gene modification in Tcm and Tem subsets was similar
suggesting that long-lived Tcm cells can be efficiently rendered HIV-resistant. Data shown is from one of
three independent experiments.
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Figure 5. Primary CD4+ T cells treated with the R5 and X4-ZFNs and challenged with HIV
have a survival advantage in vitro. (A) Primary CD4+ T cells treated with GFP, the R5-ZFN, or
two vectors encoding the R5 and X4-ZFNs were challenged with a mix of two HIV strains—the
R5-using virus Bal, and the X4-using virus HxB2. Dual ZFN treatment conferred a significant
survival advantage in vitro compared to both the GFP and R5-ZFN control. Live cells were
counted every three to four days for 32 days. Arrows indicate the time points where cells were
reactivated with anti-CD3/CD28 magnetic beads. Data is from one of three independent
experiments. (B) T7E1 analysis of ccr5 (top panel) and cxcr4 (bottom panel) gene modification
reveals that HIV challenge enriches for ccr5 and cxcr4 disrupted cells. Analysis was performed 0
and 21 days post infection. Data is from one of three independent experiments. (C) The
proportion of modified ccr5 and cxcr4 alleles in cells treated with both ZFNs increases
approximately 2-fold in the presence or absence of HIV, as measured by the T7E1 assay. Data is
shown as the mean ± SEM of three independent experiments. P-values calculated using
student’s t-test.
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Figure 6 – Dual R5- and X4-ZFN treatment confers protection in vivo. (A) Experimental timeline of the in
vivo study is shown. (B) All three treatment groups were successfully engrafted as measured 21 days postinfusion and three days prior to infection with a slight decrease in CD4+ T cell counts in ZFN groups
compared to the GFP control. (C) Dual ZFN treatment preserves CD4+ T cells in the spleen compared to
controls. Spleens were obtained from infected animals from all animals at the time of euthanasia. Human
CD4+ T cells were defined as CD45+ CD3+ CD4+ CD8- T cells by FACS. (D) Dual ZFN treatment confers
long-term protection against HIV as measured by preservation of peripheral blood CD4+ T cell counts. All
uninfected animals and 1 infected animal in the R5/X4-ZFN treated group were euthanized 34 days post
infection due xenogeneic graft-versus-host disease. Infected animals were followed for 55 days after
infection. All statistical analyses were performed using a Mann-Whitney U test. Error bars indicate the mean
± SEM.
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Figure 7 –Cells lacking both ccr5 and cxcr4 following R5/X4-ZFN treatment have a survival
advantage in vivo in the presence of HIV.
(A) The frequency of human ccr5 and cxcr4-modified genes significantly increases in the R5/X4ZFN treatment group over the course of the in vivo infection. ccr5 and cxcr4 disruption are stable
over time in the absence of HIV infection suggesting there is no significant adverse effect of dual
ZFN treatment. We performed illumina deep sequencing of the R5 and X4-ZFN target sites and
identified ZFN-induced mutations at these sites in 8/9 uninfected and 8/9 infected animals. We
were unable to obtain sequence information from one infected animal due to limiting quantities of
CD4+ T cells, and euthanized one uninfected animal following the development of GVHD, and
this animal is thus excluded. (B) We stained whole blood from infected and uninfected animals in
the R5/X4-ZFN treatment group 34 days post-infection with human antibodies to identify human
CD4+ T cells and determine surface levels of R5 and X4. Both CCR5 and CXCR4 expression
were significantly reduced on dual ZFN treated cells in the presence of HIV challenge suggesting
that coreceptor negative cells have an in vivo survival advantage due to ZFN treatment.
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A.

Figure 8. Sequence and activity of CCR5 targeted designer nucleases (A) Sequence overlap
between CCR5 ZFN binding sites (red boxes), CCR5 TALEN binding sites (Blue boxes), and
CCR5 CRISPR gRNA binding site (green) (B) The CCR5 targeted nucleases area all active at
their target loci. Gene modification (%NHEJ) is as noted, and samples are described in adjacent
table.
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A.

B.
R5X4 rearrangements
CATACAGTCAGTATCAGCTCTGTGGGTGGTTGTGTTCCAGTTTCAG
CATACAGTCAGTATCAAGTAGGGGGAAAAGTGGTTGTGTTCCAGTTTCAG
CATACAGTCAGTATCAAGTAGGGGGAAAAGTGGTTGTGTTCCAGTTTCAG

X4R5 rearrangements
TTCTACCCCAATGAC-GGGTTTCTGGAAGAATTTCCAGACATTAAA
TTCTACCCCAATGACTGACCCCCTTCTGGAAGAATTTCCAGACATTAAA
TTCTACCCCAATGACTGGGCCTAATTCTGGAAGAATTTCCAGACATTAAA
TATCTGTGACCGCCTTGCCTGC----------------TTCTGGAAGAATTTCCAGACATTAAA
TTCTACCCCAATGACTGTTTCTGGCTTCTGGGGTTAGCATTCCCAGACATTAAA
TTCTACCCCAATGACTGTTTCTGGCTTCAGGGGTTAGAATTTCCAGACATTAAA
Figure 9. Reciprocal translocations between CCR5 and CXCR4 CRISPRs following
simultaneous administration (A) Nested PCR using CCR5 and CXCR4 specific primers to
identify reciprocal translocations following simultaneous delivery of CRISPRs targeting both loci.
Expected band sizes are as noted (B) Confirmation of CCR5:CXCR4 translocations using sanger
sequencing. Representative sequences are shown
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Figure 10. Identification of VEGFA CRISPR/Cas nuclease-induced rearrangements using
nested PCR (A) T7 Endonuclease assay to measure gene disruption following delivery of
CRISPR/Cas nucleases targeting two loci (T2 and T3) in the VEGFA gene. %NHEJ is as
indicated. (B) Nested PCR on genomic DNA from 293T cells identified rearrangements between
CRISPR/Cas on- and off-target loci only in cells that received the nucleases. Expected band
sizes are as shown
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A.
VEGFA.T2:FMN1
ccggaggcggggtggagggggtcttttggaaatgcaaatctcc
cccggcgcggggtggggggggtcttttggaaatgcaaatctgc
gtggacgcggcggcgagggggtcttttggaaatgcaaatctgc
ccggaggcggggtggagggggtcttttggaaatgcaaatctgc
cggcggcggacagtggacg-56bp-gggggtcttttggaaatgcaaatctcc
ccacctcctccccggc-75bp-gcggggtggagggggtcttttggaaatgcaaatctcc
ccacctcctccccggc-75bp-gcggggtggagggggtcttttggaaatgcaaatctcc
Gccgcgggcaggggccggagcccgc-25bp/20bp-tcatgtcacatattcctctgctc
B.
VEGFA.T2:PAX6
caggggccggagcccgcgcccgg-16bp/33bp-ccaggaatattatttataaccagga
caggggccggagcccg-23bp-ggcggggtggaggggcccctaggagcgccttggtggg
caggggccggagcccg-23bp-ggcggggtggaggggcccctaggagcgccttggtggg
ggacgcggcggcgag-46bp-gcggggtggaggggcccctaggagcgccttggtggg
ggccggcggcgg-66bp-cggggtggaggggcccctaggagcgccttggtggg
C.
VEGFA.T3:MAX
gtgtgggtgagtgagtgtgtgc--3bp-cactcactcgctctctcac
gtgtgggtgagtgagtgt------7bp-cactcactcactcactcac
gtgtgggtgagt-----------13bp-cactcactcactcactcac
D.
VEGFA.T3:COMMD10
acgtgtgtgt------------27bp-cgtgaggacatttaagatcta
acgtgtgtgtctgtgtgggtgagtgag--8bp-gacatttaagatcta
tgtgggtgagtgagtgtgtgc-8bp-tttaagatcta
tgtgtgggtgagtgagtgtgtg-3bp-gtgaggacatttaagatcta
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Figure 11. Sanger sequencing reveals genomic rearrangements following treatment of
293T cells with a single VEGFA-targeting CRISPR/Cas nuclease (A) Sanger sequencing
results showing translocations between VEGFA.T2 and off-target site FMN1. (B) Sanger
sequencing results showing translocations between VEGFA.T2 and off-target site PAX6. (C)
Sanger sequencing results showing translocations between VEGFA.T3 and off-target site MAX.
(D) Sanger sequencing results showing translocations between VEGFA.T3 and off-target site
COMMD10. VEGFA sequences are in black and off-target site sequences are in blue. Deletions
are indicated as number of base pairs and may involve either or both genes, and black
nucleotides indicate mutations.
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